Journal Articles 1987-2008
1. Abdallah, A. B., Scheier, L. M., Inciardi, J. A., Copeland, J., & Cottler, L. B. (2007). A psycho-economic model of ecstasy consumption and related consequences: A multi-site study with community samples. Substance Use and Misuse, 42(11), 1651-1684.
2. Amato, L., Davoli, M., Perucci, C., Ferri, M., Faggiano, F., & Mattick, R.P. (2005). An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment 28, 321-329.
3. Anderson, R., Haas, M., & Shanahan, M. (2008). The cost-effectiveness of cervical screening in Australia: What is the impact of screening at different intervals or over a different age range? Australian and New Zealand Journal of Public Health, 32(1), 43-52.
4. Andrews, G., Henderson, A.S., & Hall, W. (2001). Prevalence, comorbidity, disability and service utilisation: An overview of the Australian National Mental Health Survey. British Journal of Psychiatry 178, 145-153.
5. Anthony, J.C. & Degenhardt, L. (2007). Projecting the impact of changes in cannabis use upon schizophrenia in England and Wales: The role of assumptions and balance in framing an evidence-based cannabis policy. Addiction 102, 515-516.
6. Baillie, A. J. & Mattick, R.P. (1996). Benzodiazepine dependence questionnaire: Development, reliability and validity. British Journal of Psychiatry 169, 276-281.
7. Baillie, A. J., Mattick, R.P., & Hall, W. (1994). Self-quitting smoking: Estimation of an unaided abstinence rate by meta-analysis. Australian Journal of Public Health 19, 29-31.
8. Baillie, A. J., Mattick, R.P., Hall, W., & Webster, P. (1994). Meta-analytic review of smoking cessation interventions. Drug and Alcohol Review 13, 157-170.
9. Baillie, A., Mattick, R. P., Webster, P., & Chen, R. (1993). People receiving treatment for drug and alcohol problems in Australia. NIDA Research Monograph Series(132), 44.
10. Baillie, A., Webster, P., & Mattick, R.P. (1992). An Australian survey of the procedures used for the treatment of opiate users. Drug and Alcohol Review 11, 343-354.
11. Baker, A., Heather, N., Wodak, A., Dixon, J., & Holt, P. (1993). Evaluation of a cognitive-behavioural intervention for HIV prevention among injecting drug users. AIDS 7, 247-256.
12. Baker, A., Kochan, N., Dixon, J., Wodak, A., & Heather, N. (1994). Drug use and HIV risk-taking behaviour among injecting drug users not currently in treatment in Sydney, Australia. Drug and Alcohol Dependence, 34(2), 155-160.
13. Baldwin, S., Lawson, A., Mooney, J., Braggins, F., Carnegie, E., McLean, G., Robertson, I., & Heather, N. (1991). Effectiveness of pre-release alcohol education courses for young offenders in a penal institution. Behavioural Psychotherapy 19, 321-331.
14. Baldwin, S., Lawson, A., Mooney, J., Braggins, F., Carnegie, E., McLean, G., Robertson, I., & Heather, N. (1991). Comparison of effectiveness of behavioural and talk-based alcohol education courses. Behavioural Psychotherapy 19, 157-172.
15. Barber, J.G., Cooper, B.K., & Heather, N. (1991). The Situational Confidence Questionare (heroin). International Journal of Addictions 26, 565-575.
16. Bell, J. (1991). Pain and addiction. Drug and Alcohol Review 10, 247-252.
17. Bell, J. (1992). Treatment dependence. Preliminary description of yet another syndrome. British Journal of Addiction 87, 1049-1054.
18. Bell, J. (1997). Australian trends in opioid prescribing for chronic, non-cancer pain, 1986-1996. Medical Journal of Australia 167, 26-29.
19. Bell, J. (1998). Self report among injecting drug users. Drug and Alcohol Dependence 51, 267-268.
20. Bell, J. (2008). Speciality recognition of addiction medicine in Australia. Addiction, 103(5), 701-702.
21. Bell, J. & Batey, W. (1992). Medicine and the addictions (Editorial). Australian and New Zealand Journal of Medicine 22, 202-203.
22. Bell, J., Burrell, T., Indig, D., & Gilmour, S. (2005). Cycling in and out of treatment; participation in methadone treatment in NSW, 1990-2002. Drug and Alcohol Dependence 81, 55-61. (abstract available)
23. Bell, J., Byron, G., Gibson, A., & Morris, A. (2004). A pilot study of buprenorphine-naloxone combination tablet (Suboxone®) in treatment of opioid dependence. Drug and Alcohol Review 23, 311-317.
24. Bell, J., DiGuisto, E., & Byth, K. (1992). Who should receive methadone maintenance? British Journal of Addiction 87, 527-532.
25. Bell, J., Hall, W., & Byth, K. (1992). Changes in criminal activity after entering methadone maintenance. British Journal of Addiction 87, 251-258.
26. Bell, J., Mattick, R., Chan, J., Hay, A., & Hall, W. (1997). Methadone maintenance and drug-related crime. Journal of Substance Abuse 9, 15-25.
27. Bell, J., Mattick, R., Hay, A., Chan, J., & Hall, W. (1997). Methadone maintenance and drug-related crime. Journal of Substance Abuse 9, 15-25.
28. Bell, J. R., Ryan, A., Mutch, C., Batey, R., & Rea, F. (2008). Optimising the benefits of unobserved dose administration for stable opioid maintenance patients: Follow-up of a randomised trial. Drug and Alcohol Dependence, 96(1-2), 183-186.
29. Bell, J., Shanahan, M., Mutch, C., Rea, F., Ryan, A., Batey, R., Dunlop, A., & Winstock, A. (2007). A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 102, 1899-1907.
30. Bell, J., Young, M.R., Masterman, S., Morris, A., Mattick, R.P., & Bammer, G. (1999). A pilot study of naltrexone-accelerated detoxification in opioid dependence. Medical Journal of Australia 171, 26- 30.
31. Bellis, M. A., Hughes, K. E., Dillon, P., Copeland, J., & Gates, P. (2007). Effects of backpacking holidays in Australia on alcohol, tobacco and drug use of UK residents. Bmc Public Health, 7.
32. Ben Abdallah, A., Scheier, L.M., Inciardi, J.A., Copeland, J. & Cottler, L.B. (2007). A psycho-economic model of ecstasy consumption and related consequences: A multi-site study with community samples. Substance Use and Misuse 42, 1651-1684.
33. Black, E. & Degenhardt, L. (2006). Drug-related aggression among injecting drug users. NSW Public Health Bulletin 17, 12.
34. Bonevski, B., Doran, C., Bailey, C., & Lowe, J. (2002). Description of an early discharge post-acute care program: Length of hospital stay, patient and carer needs and cost. Australian Health Review 25, 78-86.
35. Bonomo, Y., Coffey, C., Wolfe, R., Lynskey, M., Bowes, G., & Patton, G. (2001). Alcohol-related problem behaviours in 16-17 year old Australian students. Addiction 96, 1485-1496.
36. Boot, B., Hall, W., & Andrews, G. (1997). Disability, outcome and casemix in acute psychiatric in-patient units. British Journal of Psychiatry 171, 242-246.
37. Boot, B., McGregor, I.S., & Hall, W. (2000). MDMA (Ecstasy) neurotoxicity: Assessing and communicating the risks. Lancet 355, 1818-1821.
38. Brady, M., Dawe, S., & Richmond, R. (1998). Expanding knowledge among Aboriginal service providers on treatment options for excessive alcohol use. Drug and Alcohol Review 17, 69-76.
39. Bramley-Moore, S.R., Wodak, A.D., Day, R.O., & Lachlan, R.L. (1998). Patterns of analgesic prescribing patients with chronic non-malignant pain in NSW. The Australian Journal of Hospital Pharmacy 28, 83-88.
40. Breen, C., Degenhardt, L., Bruno, R., Roxburgh, A., & Jenkinson, R. (2004). The effects of restricting publicly subsidised temazepam capsules on benzodiazepine use among injecting drug users in Australia. Medical Journal of Australia 181, 300-304.
41. Breen, C., Degenhardt, L., Kinner, S., Bruno, R., Jenkinson, R., Matthews, A., & Newman, J. (2006). Alcohol use and risk taking among regular ecstasy users. Substance Use and Misuse 41, 1095-1109.
42. Breen, C., Harris, S., Lintzeris, N., Mattick, R.P., Hawken, L., Bell, J., Ritter, A.J., Lenné, M., & Mendoza, E. (2003). Cessation of methadone maintenance treatment using buprenorphine: Transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug and Alcohol Dependence 71, 49-55. (abstract available)
43. Breen, C., Roxburgh, A. & Degenhardt, L. (2005). Gender differences among regular injecting drug users in Sydney, Australia, 1996-2003. Drug and Alcohol Review 24, 353-358.
44. Buck, D.J., Richmond, R.L., & Mendelsohn, C.P. (2000). Cost-effectiveness analysis of a family physician delivered smoking cessation program. Preventive Medicine 31, 641-648.
45. Buhrich, N., Hodder, T., & Teesson, M. (2000). Prevalence of cognitive impairment among homeless people in inner Sydney. Psychiatric Services 51, 520-521. (abstract available)
46. Buhrich, N., Hodder, T., & Teesson, M. (2000). Lifetime prevalence of trauma among homeless people in Sydney. Australian and New Zealand Journal of Psychiatry 34, 963-966.
47. Buhrich, N., Hodder, T. & Teesson, M. (2003). Schizophrenia among homeless people in inner-Sydney: Current prevalence and historical trends. Journal of Mental Health 12, 51-57. (abstract available)
48. Burns, L. & Mattick, R.P. (2007). Using population data to examine the prevalence and correlates of neonatal abstinence syndrome. Drug and Alcohol Review 26, 487-492.
49. Burns, L., Mattick, R.P. & Cooke, M. (2006). The use of record linkage to examine illicit drug use in pregnancy. Addiction 101, 873-882.
50. Burns L., Mattick, R.P. & Cooke, M. (2006). The use of linked data to examine alcohol use in pregnancy. Alcoholism: Clinical and Experimental Research 30, 642-648.
51. Burns, L., Mattick, R.P., Lim, K., Wallace, C. (2007). Methadone in pregnancy: Treatment retention and neonatal outcomes. Addiction 102, 264-270.
52. Burns, L., Mattick, R. P., & Wallace, C. (2008). Smoking patterns and outcomes in a population of pregnant women with other substance use disorders. Nicotine & Tobacco Research, 10(6), 969-974.
53. Burns, L. & Teesson, M. (2002). Alcohol use disorders comorbid with anxiety, depression and drug use disorders: Findings from the Australian National Survey of Mental Health and Well-Being. Drug and Alcohol Dependence 68, 299-308.
54. Burns, L., Teesson, M., & O'Neill, K. (2005). The impact of comorbid anxiety and depression on alcohol treatment outcomes. Addiction, 100(6), 787-796.
55. Butler, T., Dolan, K., Ferson, M., McGuiness, L., Brown, P., & Robertson, P. (1997). Hepatitis B and C in New South Wales prisons. Prevalence and risk factors. Medical Journal of Australia 166, 127-130.
56. Butler, T., Levy, M., Dolan, K., & Kaldor, J. (2003). Drug use and its correlates in an Australian Prisoner Population. Addiction Research and Theory 11, 89-101.(abstract available)
57. Byrne, A. & Dolan, K. (1998). Methadone treatment is widely accepted in prisons in New South Wales (letter to the editor). British Medical Journal 316, 1744.
58. Cadman, M. & Bell, J. (1998). Doctors detected self-administering opioids in New South Wales, 1985-1994: Characteristics and outcomes. Medical Journal of Australia 169, 419-421.
59. Campbell, I., & Chalmers, J. (2008). Job quality and part-time work in the retail industry: An Australian case study. International Journal of Human Resource Management, 19(3), 487-500.
60. Carey, D.L., Day, R.O., Cairns, D.R., Pearce, G.A., Wodak, A.D., & Lauchlan, R.L. (1992). An attempt to influence hypnotic and sedative drug usage. Medical Journal of Australia 156, 389-393.
61. Caulkins, J. P., Dietze, P., & Ritter, A. (2007). Dynamic compartmental model of trends in Australian drug use. Health Care Management Science, 10(2), 151-162.
62. Chambers, G., Grayson, N., Shanahan, M., Chapman, M., & Sullivan, E. (2007). The inpatient birth-admission costs of singleton and multiple births after ART treatment - A comparison with spontaneously conceived births. Australian & New Zealand Journal of Obstetrics & Gynaecology, 47, A3-A4.
63. Chambers, G. M., Chapman, M. G., Grayson, N., Shanahan, M., & Sullivan, E. A. (2007). Babies born after ART treatment cost more than non-ART babies: A cost analysis of inpatient birth-admission costs of singleton and multiple gestation pregnancies. Human Reproduction, 22(12), 3108-3115.
64. Chan, J.S.K., Kuk, A.Y.C., & Bell, J. (1997). A likelihood approach to analysing longitudinal bivariate binary data. Biometrical Journal 39, 409-421.
65. Chan, J.S.K., Kuk, A.Y.C., Bell, J., & McGilchrist, C. (1998). The analysis of methadone clinic data using marginal and conditional logistic models with mixture or random effects. The Australian and New Zealand Journal of Statistics 40, 1-10.
66. Chesher, G., & Wodak, A. (1990). Evolving a new policy for illicit drugs. Journal of Drugs Issues 20, 555-561.
67. Chesher, G. & Greeley, J. (1992). Tolerance to the effects of alcohol. Alcohol, Drugs and Driving 8, 93-106.
68. Coffey, C., Carlin, J.B., Lynskey, M.L., Degenhardt, L., & Patton, G.C. (2003). Cannabis dependence in young adults: Findings from the Victorian Adolescent Health Cohort Study. Journal Salud Ciencia.
69. Coffey, C., Carlin, J.B., Degenhardt, L., Lynskey, M., Sanci, L., & Patton, G.C. (2002). Cannabis dependence in young adults: An Australian population study. Addiction 97, 187-194.(abstract available)
70. Coffey, C., Lynskey, M., Wolfe, R., & Patton, G.C. (2000). Initiation and progression of cannabis use in a population-based Australian adolescent longitudinal study. Addiction 95, 1679-1690.
71. Conigrave, K.M., Degenhardt, L.J., Whitfield, J.B., Saunders, J.B., Helander, A., & Tabakoff, B. (2002). CDT, GGT, and AST as markers of alcohol use:The WHO/ISBRA Collaborative Project. Alcoholism: Clinical and Experimental Research 26, 332-339.
72. Conigrave, K., Hall, W. & Saunders, J. B. (1995). The AUDIT questionnaire: Choosing a cut-off score. Addiction 90, 1349-1356.
73. Conroy, E., Degenhardt, L. & Day, C. (2007). Impact of drug market changes on substance-using pregnant women in three key Sydney drug markets. Women and Health 44, 93-105.
74. Cooke, M., Mattick, R.P., & Barclay, L. (1996). Predictors of brief smoking intervention in a midwifery setting. Addiction 91, 1715-1725.
75. Cooke, M., Mattick, R.P., & Campbell, E. (1998). The influence of individual and organizational factors on the reported factors on the reported smoking intervention practices of staff in 20 antenatal clinics. Drug and Alcohol Review 17, 175-185.
76. Cooke, M., Mattick, R.P., & Campbell, E. (1999). The dissemination of a smoking cessation program to 23 antenatal clinics: The predictors of program adoption by managers. Australian & New Zealand Journal of Public Health 23, 99-103.
77. Cooke, M., Mattick, R.P., & Campbell, E. (2000). A description of the adoption of the 'Fresh Start' smoking cessation programme by antenatal clinic managers. Australian Journal of Advanced Nursing 18, 13-21.
78. Cooke, M., Mattick, R.P., & Walsh, R.A. (2001). Differential uptake of a smoking cessation programme disseminated to doctors and midwives in antenatal clinics. Addiction 96, 495-506.(abstract available)
79. Cooke, M., Mattick, R.P., Walsh, R. (2001). Implementation of the ‘fresh start’ smoking cessation program in 23 antenatal clinics: A randomized controlled trial investigating two methods of dissemination. Drug and Alcohol Review 20, 19-28.
80. Copeland, J. (1992). "She who pays the piper calls the tune": A response (letter to the editor). Drug and Alcohol Review 11, 401-402.
81. Copeland, J. (1993). Feminism and Addiction (book review). Drug and Alcohol Review 12, 117-118.
82. Copeland, J. (1995). Alcohol, Gender and Culture (book review). Addiction 90, 444-445.
83. Copeland, J. (1995). Women and Substance Use (book review). Drug and Alcohol Review 14, 245.
84. Copeland, J. (1995). Addictive Behaviors in Women (book review). Drug and Alcohol Review 14, 338.
85. Copeland, J. (1995). Maturing Out: An Empirical Study of Personal Histories and Processes in Hard-drug Addiction (book review). Drug and Alcohol Review 14, 340-341.
86. Copeland, J. (1997). A qualitative study of the perceptions of treatment services and 12-step programs among women who self-managed change in addictive behaviours. Journal of Substance Abuse Treatment 13, 1-8.
87. Copeland, J. (1998). Gender and Addictions: Men and Women in Treatment (book review). Addiction 93, 1599-1600.
88. Copeland, J. (1998). A qualitative study of self-managed change in substance dependence among women. Contemporary Drug Problems 25, 321-345.
89. Copeland, J. (1999). Women and drink driving (letter). Drug and Alcohol Review 18, 113.
90. Copeland, J. (2001). Mothers and illicit drugs: Transcending the myths (book review). Addiction 96, 783.
91. Copeland, J. (2001). Women’s Perspectives on Drugs and Alcohol: The Vicious Circle (book review). Addiction 96, 1681-1685.
92. Copeland, J. (2001). Nursing interventions for cannabis use disorder: Part 1 Prevalence and harms. Pulse: Information Sheet of the Royal College of Nursing Australia, 1-2.
93. Copeland, J. (2001). Nursing interventions for cannabis use disorder: Part 2 Prevalence and harms. Pulse: Information Sheet of the Royal College of Nursing Australia, 1-2.
94. Copeland, J. (2002). Dealing: Women in the Drug Economy (book review). Australian and New Zealand Journal of Public Health 26, 292.
95. Copeland, J. (2002). Drug Misuse and Motherhood (book review). Addiction 97, 1228.
96. Copeland, J. (2003). The Handbook of Addiction Treatment for Women (book review). Drug and Alcohol Review 22, 96-97.
97. Copeland, J. (2004). Developments in the treatment of cannabis use disorder. Current Opinion in Psychiatry 17, 161-167.
98. Copeland, J. (2005). Addiction and Life Course (book review). Addiction 100, 1032-1033.
99. Copeland, J. (2005). Cannabis problems and their management. Drugs and Alcohol Today 5, 20-25.
100. Copeland, J. (2006). Management of cannabis use disorder. Directions in Addiction Treatment & Prevention 10, 15-24.
101. Copeland, J. & Conroy, A. (2001). Australian National Minimum Data Set for Clients of Alcohol and Other Drug Treatment Services: Findings of the national pilot and developments in implementation. Drug and Alcohol Review 20, 295-298.
102. Copeland, J. & Dillon, P. (2005). The health and psycho-social consequences of ketamine use. International Journal of Drug Policy 16, 122-131.
103. Copeland , J., Dillon, P. & Gascoigne, M. (2006). Ecstasy and the concomitant use of pharmaceuticals. Addictive Behaviors 31, 367-370.
104. Copeland, J. & Hall, W. (1992). A comparison of predictors of treatment drop-out of women seeking drug and alcohol treatment in a specialists women’s and two traditional mixed-sex treatment services. British Journal of Addiction 87, 1293-1302.
105. Copeland, J. & Hall, W. (1992). A comparison of women seeking drug and alcohol treatment in a specialist women’s & two traditional mixed-sex treatment services. British Journal of Addiction 87, 1293-1302.
106. Copeland, J., Hall, W., Didcott, P.,& Biggs, V. (1993). A comparison of a specialist women’s alcohol and other drug treatment service with two traditional mixed-sex services: Client characteristics and treatment outcome. Drug and Alcohol Dependence 32, 81-92.
107. Copeland, J., Howard, J., & Fleischmann, S. (1998). Gender, HIV knowledge and risk-taking behaviour among substance using adolescents in custody in New South Wales. Journal of Substance Misuse 3, 206-212.
108. Copeland, J., Howard, J., Keogh, T., & Seidler, K. (2003). Patterns and correlates of substance use amongst juvenile detainees in New South Wales 1989-1999. Drug and Alcohol Review 22, 15-20.(abstract available)
109. Copeland, J., Howard, J., Keogh, T., & Seidler, K. (2003). Drugs and blood-borne viruses: Knowledge and risk-taking behaviour among detained adolescents in New South Wales. International Journal of Forensic Psychology 1, 85-91.
110. Copeland, J. & Indig, D. (2004). Patterns and correlates of treatment: Findings of the 2000-2001 NSW minimum dataset of clients of alcohol and other drug treatment services. Drug and Alcohol Review 23, 185-194.
111. Copeland, J. & Martin, G. (2004). Web-based interventions for substance use disorders: A qualitative review. Journal of Substance Abuse Treatment 26, 109-116.(abstract available)
112. Copeland, J. & Maxwell, J.C. (2007). Correlates and outcomes of cannabis treatment among legally coerced versus non-coerced adults in Texas. BMC Public Health 7:111.
113. Copeland, J., Peters, R., & Dillon, P. (1998). Anabolic-androgenic steroid dependence in a woman (correspondence). Australian and New Zealand Journal of Psychiatry 32, 589.
114. Copeland, J., Peters, R., & Dillon, P. (1998). A study of 100 anabolic-androgenic steroid users (letter to the editor). Medical Journal of Australia 168, 311.
115. Copeland, J., Peters, R., & Dillon, P. (2000). Anabolic-androgenic steroid use disorders among a sample of Australian competitive and recreational users. Drug and Alcohol Dependence 60, 91-96.
116. Copeland, J. & Rankin, J. (1997). Maximising the opportunity for a minimum data set (Editorial). Drug and Alcohol Review 16, 205-206.
117. Copeland, J., Rees, V. & Swift, W. (1999). Health concerns and help-seeking among a sample entering treatment for cannabis dependence (correspondence). Australian Family Physician 28, 540-541.
118. Copeland, J., Stevenson, R.J., Gates, P., & Dillon, P. (2007). Young Australians and alcohol: The acceptability of ready-to-drink (RTD) alcoholic beverages among 12-30 year olds. Addiction 102, 1740-1746.
119. Copeland, J., Swift, W., Howard, J., Roffman, R.A., Stephens, R.S. & Berghuis, J. (2001). A randomised controlled trial of brief interventions for cannabis problems among young offenders. Drug and Alcohol Dependence 63, s32.(abstract available)
120. Copeland, J., Swift, W., & Rees, V. (2000). Brief interventions for cannabis dependence. DrugWise February, 51-52.
121. Copeland, J., Swift, W., & Rees, V. (2001). Clinical profile of participants in a brief intervention program for cannabis use disorder. Journal of Substance Abuse Treatment 20, 45-52.(abstract available)
122. Copeland, J., Swift, W. & Reid, A. (2004). Young cannabis users’ attitudes and beliefs about cannabis drug education. Journal of Drug Education and Awareness 1, 119-127.
123. Copeland, J., Swift, W., Roffman, R., & Stephens, R. (2001). A randomised controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. Journal of Substance Abuse Treatment 21, 55-64.(abstract available)
124. Crawford, J. & Heather, N. (1987). Public attitudes to the disease concept of alcoholism. International Journal of the Addictions 22, 1129-1138.
125. Crisp, B.R., Barber, J.G., Ross, M.W., Wodak, A., Gold, J., & Miller, M.E. (1993). Injecting drug users and HIV/AIDS: Risk behaviours and risk perception. Drug and Alcohol Dependence 33, 73-80.
126. Crofts, N., Jolley, D., Kaldor, J., van Beek, I., & Wodak, A. (1997). Epidemiology of hepatitis C virus infection among injecting drug users in Australia. Journal of Epidemiology and Community Health 51, 692-697.
127. Cruickshank, C. C., Montebello, M. E., Dyer, K. R., Quigley, A., Blaszczyk, J., Tomkins, S., et al. (2008). A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal. Drug and Alcohol Review, 27(3), 326-333.
128. Darke, S. (1991). A brief intervention to reduce risk-taking behaviour among injecting drug users. Newsletter of the International Working Group on AIDS and Drug Use 5 (May), 61.
129. Darke, S. (1991). AIDS. Sexual Behaviour and Intravenous Drug Use (book review). Drug and Alcohol Review 10, 287.
130. Darke, S. (1992). AIDS and Alcohol/Drug Abuse. Psychosocial Research (book review). Drug and Alcohol Review 11, 207.
131. Darke, S. (1992). Cocaine, AIDS, and Intravenous Drug Use (book review). British Journal of Addiction 87, 1604.
132. Darke, S. (1992). Injecting drug users and Human Immunodeficiency Virus: What do we know? Drug and Alcohol Review 11, 153-161.
133. Darke, S. (1992). The measurement of outcome in opiate treatment evaluation studies. Drug and Alcohol Review 11, 169-175.
134. Darke, S. (1994). The use of benzodiazepines among injecting drug users. Drug and Alcohol Review 13, 63-69.
135. Darke, S. (1994). Benzodiazepine use among injecting drug users: Problems and implications (Editorial). Addiction 89, 379-382.
136. Darke S. (1994). The prescribing of benzodiazepines to injecting drug users. A reply to Dr Seivewright (letter to the editor). Addiction 89, 1703.
137. Darke, S. (1995) Ne'er the twain. Comments on Dr McKeganey's Editorial (Invited commentary). Addiction 90, 761-762.
138. Darke, S. (1995). Methodological Issues in AIDS Behavioural Research (book review). Addiction 90, 993-994.
139. Darke, S. (1996). Psychotherapy, Psychological Treatments and the Addictions (book review). British Medical Journal 312, 1309.
140. Darke, S. (1997). Source Book of Substance Abuse and Treatment (book review). Addiction 92, 1037.
141. Darke, S. (1998). Self-report among injecting drug users: A review. Drug and Alcohol Dependence 51, 253-263.
142. Darke, S. (1998). Antisocial personality disorder, psychopathy and injecting heroin use. Drug and Alcohol Dependence 52, 63-69.
143. Darke, S. (1999). Heroin in the Age of Crack Cocaine (book review). Contemporary Psychology 44, 95-97.
144. Darke, S. (1999). Attacking overdose on the home front. Comments on Strang et al "Preventing opiate overdose fatalities with take-home naloxone: Prelaunch study of possible impact and acceptability". Addiction 94, 205.
145. Darke, S. (2001). The Impact of Harm Reduction Based Methadone Treatment on HIV Infection and Mortality (book review). Addiction 96, 1072.
146. Darke, S. (2002). UK Drugs Unlimited. New Research and Policy Lessons on Illicit Drug Use (book review). Addiction 97, 240-241.
147. Darke, S. (2003). Polydrug use and overdose: Overthrowing old myths. Addiction 98, 711.
148. Darke, S. (2004). Heroin supply and health: New perspectives (Editorial). Addiction 99, 275.
149. Darke, S. (2006). Preventing Harmful Substance Use: The Evidence for Policy and Practice (book review). Addiction 101, 902-903.
150. Darke, S. (2008). From the can to the coffin: Deaths among recently released prisoners. Addiction, 103, 256-257.
151. Darke, S. (2008). Truth is not always found in the laboratory. Addiction, 103(7), 1066-1067.
152. Darke, S., Baker, A., Dixon, J., Wodak, A., & Heather, N. (1992). Drug use and HIV risk-taking behaviour among clients in methadone maintenance treatment. Drug and Alcohol Dependence 29, 263-268.
153. Darke, S., Cohen, J., Ross, J., Hando, J., & Hall, W. (1994). Transitions between routes of administration of regular amphetamine users. Addiction 89, 1077-1083.
154. Darke, S., & Duflou, J. (2008). Toxicology and circumstances of death of homicide victims in New South Wales, Australia 1996-2005. Journal of Forensic Sciences, 53(2), 447-451.
155. Darke, S., Duflou, J. & Kaye, S. (2007). Comparative toxicology of fatal heroin overdose cases and morphine positive homicide victims. Addiction 102, 1793-1797.
156. Darke, S., Finlay-Jones, R., Kaye, S., & Blatt, T. (1996). Anti-social personality disorder and response to methadone maintenance treatment. Drug and Alcohol Review 15, 271-276.(abstract available)
157. Darke, S., Guinan, J., & Gold, J. (1991). The injecting and sexual behaviour of intravenous drug users. Medical Journal of Australia, 154(4), 294.
158. Darke, S. & Hall, W. (1990). The injecting and sexual behaviour of intravenous drug users (letter to the editor). Medical Journal of Australia 153, 43.
159. Darke, S. & Hall, W. (1995). Levels and correlates of polydrug use among heroin users and regular amphetamine users. Drug and Alcohol Dependence 39, 231-235.
160. Darke, S. & Hall, W. (1997). The distribution of naloxone to heroin users. Addiction 92, 1195-1199.
161. Darke, S. & Hall, W. (2003). Heroin overdose: Research and evidence-based intervention. Journal of Urban Health: Bulletin of the New York Academy of Medicine 80, 189-200.(abstract available)
162. Darke, S., Hall, W., & Carless, J. (1990). Drug use, injecting practices, and sexual behaviour of opioid users in Sydney, Australia. British Journal of Addiction 85, 1603-1609.
163. Darke, S., Hall, W., & Carless, J. (1990). The injecting and sexual behaviour of intravenous drug users in Sydney (letter to the editor). Medical Journal of Australia 152, 488.
164. Darke, S., Hall, W., Heather, N., Ward, J., & Wodak, A. (1991). The reliability and validity of a scale to measure HIV risk-taking among intravenous drug users. AIDS 5,181-185.
165. Darke, S., Hall, W., Heather, N., Wodak, A., & Ward, J. (1992). Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opioid users: The Opiate Treatment Index. British Journal of Addiction 87, 593-602.
166. Darke, S., Hall, W., Kaye, S., Ross, J., & Duflou, J. (2002). Hair morphine concentrations of fatal heroin overdose cases and living heroin users. Addiction 97, 977-984.(abstract available)
167. Darke, S., Hall, W., & Ross, M.W. (1992). Benzodiazepine prescribing and injecting drug users (letter to the editor). Medical Journal of Australia 157, 573-574.
168. Darke, S., Hall, W., Ross, M.W., & Wodak, A. (1992). Benzodiazepine use and HIV risk-taking behaviour among injecting drug users. Drug and Alcohol Dependence 31, 31-36.
169. Darke, S., Hall, W., & Swift, W. (1994). Prevalence, symptoms and correlates of anti-social personality disorder among methadone maintenance clients. Drug and Alcohol Dependence 34, 253-257.
170. Darke, S., Hall, W., & Swift, W. (1994). Geographical differences in risk-taking among Sydney methadone maintenance patients: A comparison of inner city and outer south western methadone maintenance patients. Drug and Alcohol Review 13, 301-305.
171. Darke, S., Hall, W., Weatherburn, D. & Lind, B. (1999). Fluctuations in heroin purity and the incidence of fatal heroin overdose. Drug and Alcohol Dependence 54, 155-162.
172. Darke, S., Havard, A., Ross, J., Williamson, A., Mills, K., & Teesson, M. (2007). Changes in the use of medical services and prescription drugs among heroin users over two years. Drug and Alcohol Review 26, 153 – 159.
173. Darke, S., Heather, N., Hall, W., Ward, J., & Wodak, A. (1991). Estimating drug consumption in opioid users: Reliability and validity of a ‘recent use episodes’ method. British Journal of Addiction 86, 1311-1316.
174. Darke, S., Hetherington, K., Ross, J., Lynskey, M., & Teesson, M. (2004). Non-injecting routes of administration among entrants to three treatment modalities for heroin dependence. Drug and Alcohol Review 23, 177-183.
175. Darke, S. & Kaye, S. (2004). Attempted suicide among injecting and non-injecting cocaine users in Sydney, Australia. Journal of Urban Health 81, 505-515.
176. Darke, S., Kaye, S. & Duflou, J. (2005). Cocaine-related fatalities in New South Wales, Australia 1993-2002. Drug and Alcohol Dependence 77, 107-114.
177. Darke, S., Kaye, S. & Duflou, J. (2006). Systemic disease among cases of fatal opioids toxicity. Addiction 101, 1299-1305.
178. Darke, S., Kaye, S. & Duflou, J. (2006). Comparative cardiac pathology among deaths due to cocaine toxicity, opioids toxicity and non-drug-related causes. Addiction 101, 1771-1777.
179. Darke, S., Kaye, S., & Finlay-Jones, R. (1998). Drug use and injection risk-taking among prison methadone maintenance patients. Addiction 93, 1161-1167.
180. Darke, S., Kaye, S., & Finlay-Jones, R. (1998). Factor structure of psychopathy among methadone maintenance patients. Journal of Personality Disorders 12, 162-171.
181. Darke, S., Kaye, S., & Finlay-Jones, R. (1998). Antisocial personality disorder, psychopathy and injecting heroin use. Drug and Alcohol Dependence 52, 63-69. (abstract available)
182. Darke, S., Kaye, S., McKetin, R., & Duflou, J. (2008). Major physical and psychological harms of methamphetamine use. Drug and Alcohol Review, 27(3), 253-262.
183. Darke, S., Kaye, S. & Ross, J. (1999). Transitions between the injection of heroin and amphetamines. Addiction 94, 1795-1803.
184. Darke, S., Kaye, S. & Ross, J. (2001). Geographical injecting locations among injecting drug users in Sydney, Australia. Addiction 96, 241-246.
185. Darke, S., Kaye, S., & Topp, L. (2002). Cocaine use in New South Wales, Australia, 1996-2000: 5 year monitoring of trends in price, purity, availability and use from the illicit drug reporting system. Drug and Alcohol Dependence 67, 81-88. (abstract available)
186. Darke, S., Kelaher, M., Hall, W., & Flaherty, B. (1996) Characteristics of admissions to residential drug treatment agencies in New South Wales, 1988-1992: Illicit drug problems. Drug and Alcohol Review 15, 127-132.
187. Darke, S., Kelly, E. & Ross, J. (2004). Drug driving among injecting drug users in Sydney, Australia: Prevalence, risk factors and risk perceptions. Addiction 99, 177-185. (abstract available)
188. Darke, S. & Mattick, R.P. (1996). Commentary on Lintzeris et al. Drug and Alcohol Review 15, 197-198.
189. Darke, S., Mattick, R.P. & Degenhardt, L. (2003). The ratio of non-fatal to fatal heroin overdose. Addiction 98, 1169-1171.
190. Darke, S. & Ross, J. (1997). Polydrug dependence and psychiatric comorbidity among heroin injectors. Drug and Alcohol Dependence 48, 135-141.
191. Darke, S. & Ross, J. (1997). Overdose risk perceptions and behaviours among heroin users in Sydney, Australia. European Addiction Research 3, 87-92.
192. Darke, S. & Ross, J. (1999). Heroin-related deaths in South Western Sydney, Australia, 1992-96. Drug and Alcohol Review 18, 39-46.
193. Darke, S. & Ross, J. (2000). The use of antidepressants among injecting drug users in Sydney, Australia. Addiction 95, 407-417. (abstract available)
194. Darke, S. & Ross, J. (2000). Fatal heroin overdoses resulting from non-injecting routes of administration, NSW, Australia, 1992-1996. Addiction 95, 569-573. (abstract available)
195. Darke, S. & Ross, J. (2000). Heroin-related deaths in regional New South Wales. 1992-96. Drug and Alcohol Review 19, 35-40. (abstract available)
196. Darke, S. & Ross, J. (2001). The relationship between suicide and heroin overdose among methadone maintenance patients in Sydney, Australia. Addiction 96, 1443-1453. (abstract available)
197. Darke, S. & Ross, J. (2002). Suicide among heroin users: Rates, risk factors and methods. Addiction 97, 1383-1394.
198. Darke, S., Ross, J., & Cohen, J. (1994). The use of benzodiazepines among regular amphetamine users. Addiction 89, 1683-1690.
199. Darke, S., Ross, J., Cohen, J., Hando, J., & Hall, W. (1995). Injecting and sexual risk-taking behaviour among regular amphetamine users. AIDS Care 7, 17-24.
200. Darke, S., Ross, J., & Hall, W. (1995). Benzodiazepine use among injecting heroin users. Medical Journal of Australia 162, 645-647.
201. Darke, S., Ross, J., & Hall, W. (1996). Overdose among heroin users in Sydney, Australia I. Prevalence and correlates of non-fatal overdose. Addiction 91, 405-411. (abstract available)
202. Darke, S., Ross, J., & Hall, W. (1996). Overdose among heroin users in Sydney, Australia II. Responses to overdose. Addiction 91, 413-417. (abstract available)
203. Darke, S., Ross, J., & Hall, W. (1996). Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. Drug and Alcohol Dependence 43, 191-198.
204. Darke, S., Ross, J. & Kaye, S. (2001). Physical injecting sites among injecting drug users in Sydney, Australia. Drug and Alcohol Dependence 62, 77-82. (abstract available)
205. Darke, S., Ross, J. & Lynskey, M. (2003). The relationship of conduct disorder to attempted suicide and drug use history among methadone maintenance patients. Drug and Alcohol Review 22, 21-25. (abstract available)
206. Darke, S., Ross, J., Lynskey, M., & Teesson, M. (2004). Attempted suicide among entrants to three treatment modailities for heroin dependence in the Australian Treatment Outcome Study (ATOS): Prevalence and risk factors. Drug and Alcohol Dependence 73, 1-10. (abstract available)
207. Darke, S., Ross, J., Mills, K. L., Williamson, A., Havard, A., & Teesson, M. (2007). Patterns of sustained heroin abstinence amongst long-term, dependent heroin users: 36 months findings from the Australian Treatment Outcome Study (ATOS). Addictive Behaviors, 32(9), 1897-1906.
208. Darke, S., Ross, J., & Teesson, M. (2005). Twelve-month outcomes for heroin dependnce treatments: Does route of administration matter? Drug and Alcohol Review 24, 165-172.
209. Darke, S., Ross, J. & Teesson, M. (2007). The Australian Treatment Outcome Study (ATOS): What have we learnt about treatment for heroin dependence? Drug and Alcohol Review 26, 49-54.
210. Darke, S., Ross, J., Teesson, M., Ali, R., Cooke, R., Ritter, A., & Lynskey, M. (2005). Factors associated with 12 months continuous heroin abstinence: Findings from the Australian Treatment Outcome Study (ATOS). Journal of Substance Abuse Treatment 28, 255-263.
211. Darke, S., Ross, J., Teesson, M., & Lynksey, M. (2003). Health service utilization and benzodiazepine use among heroin users: Findings from the Australian Treatment Outcome Study (ATOS). Addiction 98, 1129-1135. (abstract available)
212. Darke, S., Ross, J., Williamson, A., Mills, K., Havard, A., & Teesson, M. (2007). Patterns and correlates of attempted suicide by heroin users over a 3-year period: Findings from the Australian Treatment Outcome Study. Drug and Alcohol Dependence 87, 146-152.
213. Darke, S., Ross, J., Williamson, A., Mills, K., Havard, A., & Teesson, M. (2007). Borderline personality disorder and persistently elevated levels of risk in 36-month outcomes for the treatment of heroin dependence. Addiction 102, 1140-1146.
214. Darke, S., Ross, J., Williamson, A., Mills, K. L., Havard, A., & Teesson, M. (2008). Injecting and noninjecting heroin administration: Transitions and treatment outcomes across 36 months. Journal of Drug Issues, 38(2), 543-557.
215. Darke, S., Ross, J., Williamson, A., & Teesson, M. (2005). The impact of borderline personality disorder on 12-month outcomes for the treatment of heroin dependence. Addiction, 100(8), 1121-1130.
216. Darke, S., Ross, J., Zador, D., & Sunjic, S. (2000). Heroin-related deaths in New South Wales. 1992-96. Drug and Alcohol Dependence 60, 141-150. (abstract available)
217. Darke, S., Sims, J., McDonald, S., & Wickes, W. (2000). Cognitive impairment among methadone maintenance patients. Addiction 95, 687-696. (abstract available)
218. Darke, S., Sunjic, S., Zador, D., & Prolov, T. (1997). A comparison of blood toxicology of heroin-related deaths and current heroin users in Sydney, Australia. Drug and Alcohol Dependence 47, 45-53. (abstract available)
219. Darke, S., Swift, W., & Hall, W. (1994). Prevalence, severity and correlates of psychological morbidity among methadone maintenance clients. Addiction 89, 229-235.
220. Darke, S., Swift, W., Hall, W., & Ross, M. (1994). Predictors of injecting and injecting risk-taking behaviour among methadone maintenance clients. Addiction 89, 331-336.
221. Darke, S., Swift, W., Hall, W., & Ross, M. (1993). Drug use, HIV risk-taking and psychosocial correlates of benzodiazepine use among methadone maintenance clients. Drug and Alcohol Dependence 34, 67-70.
222. Darke, S., Topp, L., Kaye, S. & Hall, W. (2002). Heroin use in New South Wales, Australia, 1996-2000: 5 year monitoring of trends in price, purity, availability and use from the Illicit Drug Reporting System. Addiction 97, 179-186. (abstract available)
223. Darke, S., Topp, L., & Ross, J. (2002). The injection of methadone and benzodiazepines among Sydney IDU 1996-2000: 5 year monitoring of trends from the Illicit Drug Reporting System (IDRS). Drug and Alcohol Review 21, 35-40. (abstract available)
224. Darke, S., Ward, J., Zador, D., & Swift, G. (1991). A scale for measuring the health status of opiate users. British Journal of Addiction 86, 1317-1322.
225. Darke, S., Williamson, A., Ross, J., Mills, K., Havard, A., & Teesson, M. (2007). Patterns of nonfatal heroin overdose over a 3-year period: Findings from the Australian Treatment Outcome Study. Journal of Urban Health 84, 283-291.
226. Darke, S., Williamson, A., Ross, J., & Teesson, M. (2005). Attempted suicide among heroin users: 12-month outcomes from the Australian Treatment Outcome Study (ATOS). Drug and Alcohol Dependence 78, 177-186.
227. Darke, S., Williamson, A., Ross, J., & Teesson, M. (2005). Non-fatal heroin overdose, treatment exposure and client characteristics: Findings from the Australian treatment outcome study (ATOS). Drug and Alcohol Review 24, 425-432. (abstract available)
228. Darke, S., Williamson, A., Ross, J., & Teesson, M. (2006). Residential rehabilitation for the treatment of heroin dependence: Sustained heroin abstinence and drug-related problems 2 years after treatment entrance. Addictive Disorders & Their Treatment 5, 9-18.
229. Darke, S., Williamson, A., Ross, J., & Teesson, M. (2006). Reductions in heroin use are not associated with increases in other drug use: 2-year findings from the Australian Treatment Outcome Study. Drug and Alcohol Dependence 84, 201-205.
230. Darke, S., Williamson, A., Ross, J., Teesson, M., & Lynskey, M. (2004). Borderline personality disorder, antisocial personality disorder and risk-taking among heroin users: Findings from the Australian Treatment Outcome Study (ATOS). Drug and Alcohol Dependence 74, 77-83.
231. Darke, S., Wodak, A., Hall, W., Heather, N., & Ward, J. (1992). Prevalence and predictors of psychopathology among opioid users. British Journal of Addiction 87, 771-776.
232. Darke, S. & Zador, D. (1996). Fatal heroin overdose: A review. Addiction 91, 1765-1772.
233. Darke, S., Zador, D., & Sunjic, S. (1997). Heroin-related deaths in south-western Sydney (letter to the editor). Medical Journal of Australia 167, 107.
234. Dawe, S., Rees, V. & Mattick, R. (2002). Efficacy of moderation-oriented cue exposure for problem drinkers: A randomized controlled trial. Journal of Consulting and Clinical Psychology 70, 1045-1050.
235. Davoli, M., Ferri, M., Ali, R., Auriacombe, M., Faggiano, F., Mattick, R.P., Farrell, M. & Ling, W. (2000). The Cochrane Review Group on drugs and alcohol. Addiction 95, 1143-1474.
236. Day, C., Collins, L., Degenhardt, L., Thetford, C., & Maher, L. (2004). Reliability of heroin users’ reports of drug use behaviour using a 24 month timeline follow-back technique to assess the impact of the Australian heroin shortage. Addiction Research and Theory 12, 433-443.
237. Day, C., Conroy, E., Lowe, J., Page, J., & Dolan, K. (2006).Patterns of drug use and associated harms among rural injecting drug users: Comparisons with metropolitan injecting drug users. Australian Journal of Rural Health 14, 120-125.
238. Day, C., Degenhardt, L., Gilmour, S., & Hall, W. (2004). Effects of reduction in heroin supply on injecting drug use: Analysis of data from needle and syringe programmes. BMJ 329,428-429.
239. Day, C., Degenhardt, L., Gilmour, S., & Hall, W. (2005). The impact of changes to heroin supply on blood-borne virus notifications and injecting related harms in New South Wales, Australia. BMC Public Health 5:84.
240. Day, C., Degenhardt, L.. & Hall, W. (2006). Documenting the heroin shortage in New South Wales. Drug and Alcohol Review 25, 297 – 305.
241. Day, C., Degenhardt, L.. & Hall, W. (2006). Changes in the initiation of heroin use after a reduction in heroin supply. Drug and Alcohol Review 25, 307-313.
242. Day, C. & Dolan, K. (2006). Correlates of hepatitis C testing among heroin injectors in Sydney. Health Promotion Journal of Australia 17, 70-72.
243. Day, C., Jayasuriya, R. & Stone, G. (2004). Hepatitis C-related discrimination in New South Wales. Australian Health Review 27, 58-61.
244. Day, C., Nassirimanesh, B., Shakeshaft, A., & Dolan, K. (2006). Patterns of drug use among a sample of drug users and injecting drug users attending a GP clinic in Iran. Harm Reduction Journal 3:2.
245. Day, C., Ross, J., Dietze, P., & Dolan, K. (2005). Initiation to heroin injecting among heroin users in Sydney, Australia: Cross sectional survey. Harm Reduction Journal 2:2.
246. Day, C., Ross, J. & Dolan, K. (2003). Hepatitis C-related discrimination among heroin users in Sydney: Drug user or hepatitis C discrimination? Drug and Alcohol Review 22, 317-321. (abstract available)
247. Day, C., Ross, J. & Dolan, K. (2004). Characteristics of Aboriginal Injecting Drug Users in Sydney, Australia: Prison history, hepatitis C status and drug treatment experiences. Journal of Ethnicity in Substance Abuse 2, 51-58. (abstract available)
248. Day, C. & Topp, L. (2003). Safety in drug and alcohol research (Editorial). Addiction 98, 1641-1643.
249. Day, C., Topp, L., Rouen, D., Darke, S., Hall, W., & Dolan, K. (2003). Decreased heroin availability in Sydney in early 2001. Addiction 98, 93-95. (abstract available)
250. Day, C., White, B., Ross, J. & Dolan, K. (2003). Poor knowledge and low coverage of hepatitis B vaccination among injecting drug users in Sydney. Australian and New Zealand Journal of Public Health 27, 558.
251. Dean, A.J., Bell, J., Christie, M.J., & Mattick, R.P. (2004). Depressive symptoms during buprenorphine versus methadone maintenance: Findings from a randomized controlled trial. European Psychiatry 19, 510-513.
252. De Burgh, S., Mant, A., Mattick, R.P., Donnelly, N., Hall, W., & Bridges-Webb, C. (1994). A controlled trial of educational visiting to improve benzodiazepine prescribing in general practice. Australian Journal of Public Health 19, 142-148.
253. Degenhardt, L. (2000). Interventions for people with alcohol use disorders and an intellectual disability: A review of the literature. Journal of Intellectual & Developmental Disability 25, 135-146. (abstract available)
254. Degenhardt, L. (2003). The link between cannabis use and psychosis: Furthering the debate (Editorial). Psychological Medicine 33, 3-6.
255. Degenhardt, L. (2003). GHB: Un analisis. Adicciones 15 (Supl 2), 167-177.
256. Degenhardt, L. (2005). Illicit drug users respond to price changes (book review). Nordic Studies on Alcohol and Drugs 22, 185-188.
257. Degenhardt, L. (2005). Drug use and risk behaviour among regular ecstasy users: Does sexuality make a difference? Culture, Health & Sexuality 7,
599-614.
258. Degenhardt, L., Baker, A., & Maher, L. (2008). Methamphetamine: Geographic areas and populations at risk, and emerging evidence for effective interventions. Drug and Alcohol Review, 27(3), 217-219.
259. Degenhardt, L., Barker, B. & Topp, L. (2004). Patterns of ecstasy use in Australia: Findings from a national household survey. Addiction 99, 187-195.
260. Degenhardt, L., Black, E., Breen, C., Bruno, R., Kinner, S., Roxburgh, A., Fry, C., Jenkinson, R., Ward, J., Fetherston, J., Weekley, J., & Fischer, J. (2006). Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. Drug and Alcohol Review 25, 403-412.
261. Degenhardt, L., Bohnert, K. M., & Anthony, J. C. (2007). Case ascertainment of alcohol dependence in general population surveys: 'Gated' versus 'ungated' approaches. International Journal of Methods in Psychiatric Research, 16, 111-123.
262. Degenhardt, L., Bohnert, K. M., & Anthony, J. C. (2008). Assessment of cocaine and other drug dependence in the general population: "Gated" versus "ungated" approaches. Drug and Alcohol Dependence, 93(3), 227-232.
263. Degenhardt, L., Cheng, H. & Anthony, J.C. (2007). Assessing cannabis dependence in community surveys: Methodological issues. International Journal of Methods in Psychiatric Research 16, 43–51.
264. Degenhardt, L., Chiu, W. T., Sampson, N., Kessler, R. C., Anthony, J. C., Angermeyer, M., et al. (2008). Toward a global view of alcohol, tobacco, cannabis, and cocaine use: Findings from the WHO World Mental Health Surveys. Plos Medicine, 5(7), 1053-1067.
265. Degenhardt, L., Coffey, C., Carlin, J.B., Moran, P., & Patton, G.C. (2007). Who are the new amphetamine users? A 10-year prospective study of young Australians. Addiction 102, 1269–1279.
266. Degenhardt, L., Coffey, C., Carlin, J.B., Swift, W., & Patton, G.C. (2008). Are diagnostic orphans at risk of developing cannabis abuse or dependence? Four-year follow-up of young adult cannabis users not meeting diagnostic criteria. Drug and Alcohol Dependence 92, 86–90.
267. Degenhardt, L., Coffey, C., Moran, P., Carlin, J.B., & Patton, G. (2007). The predictors and consequences of adolescent amphetamine use: Findings from the Victoria Adolescent Health Cohort Study. Addiction 102, 1076–1084.
268. Degenhardt, L., Conigrave, K., Wutzke, S., & Saunders, J. (2001). The validity of an Australian modification of the AUDIT questionnaire. Drug and Alcohol Review 20, 143-153. (abstract available)
269. Degenhardt, L., Conroy, E., Day, C., Gilmour, S., & Hall, W. (2005). The impact of a reduction in drug supply on demand for and compliance with treatment for drug dependence. Drug and Alcohol Dependence 79, 129-135.
270. Degenhardt, L., Conroy, E., Gilmour, S., & Collins, L. (2005). The effect of a reduction in heroin supply in Australia upon drug distribution and acquisitive crime. British Journal of Criminiology 45, 2-24.
271. Degenhardt, L., Conroy, E., Gilmour, S., & Hall, W. (2005). The effect of a reduction in heroin supply on fatal and non-fatal drug overdoses in New South Wales, Australia. Medical Journal of Australia 182, 20-23.
272. Degenhardt, L., Darke, S., & Dillon, P. (2002). GHB use among Australians: Characteristics, use patterns and associated harms. Drug and Alcohol Dependence 67, 89-94. (abstract available)
273. Degenhardt, L., Darke, S. & Dillon, P. (2003). The prevalence and correlates of gamma-hydroxybutyrate (GHB) overdose among Australian users. Addiction 98, 199-204. (abstract available)
274. Degenhardt, L., Day, C., Conroy, E., & Gilmour, S. (2006). Examining links between cocaine use and street-based sex work in New South Wales, Australia. The Journal of Sex Research 43, 107-114.
275. Degenhardt, L., Day, C., Conroy, E., Gilmour, S., & Hall, W. (2005). Age differentials in the impacts of reduced heroin: Effects of a ‘heroin shortage’ in NSW, Australia. Drug and Alcohol Dependence 79, 397-404.
276. Degenhardt, L., Day, C., Dietze, P., Pointer, S., Conroy, E., Collins, L., & Hall, W. (2005). Effects of a sustained heroin shortage in three Australian states. Addiction 100, 908-920.
277. Degenhardt, L., Day, C., Gilmour, S., & Hall, W. (2005). Patterns of illicit drug use in NSW, Australia following a reduction in heroin supply. International Journal of Drug Policy 16, 300-307.
278. Degenhardt, L., Day, C., Gilmour, S., & Hall, W. (2006). The ‘lessons’ of the Australian ‘heroin shortage’. Substance Abuse, Treatment, Prevention and Policy 1:11.
279. Degenhardt, L., Day, C., Hall, W., Conroy, E., & Gilmour, S. (2005). Was an increase in cocaine use among injecting drug users in New South Wales, Australia, accompanied by an increase in violent crime? BMC Public Health 5:40.
280. Degenhardt, L., Dillon, P., Duff, C., & Ross, J. (2006). Driving, drug use behaviour and risk perceptions of nightclub attendees in Victoria, Australia. International Journal of Drug Policy 17, 41-46.
281. Degenhardt, L., & Dunn, M. (2008). The epidemiology of GHB and ketamine use in an Australian household survey. International Journal of Drug Policy, 19(4), 311-316.
282. Degenhardt, L., Gascoigne, M., & Howard, J. (2002). Young people’s drug use when heroin is less available. Youth Studies Australia 21,11-16. (abstract available)
283. Degenhardt, L. Gibson, A., Mattick, R.P. & Hall, W. (2008). Depot naltrexone use for opioid dependence in Australia: Large-scale use of an unregistered medication in the absence of data on safety and efficacy (Editorial). Drug and Alcohol Review 27, 1-3.
284. Degenhardt, L. & Hall, W. (2001). The association between psychosis and problematical drug use among Australian adults: Findings from the National Survey of Mental Health and Well-Being. Psychological Medicine 31, 659-668. (abstract available)
285. Degenhardt, L. & Hall, W. (2001) The relationship between tobacco use, substance use disorders and mental health: Results from the National Survey of Mental Health and Well-being. Nicotine and Smoking Research 3, 225-234.
286. Degenhardt, L. & Hall, W. (2002). Cannabis and psychosis. Current Psychiatry Reports 4, 191-196. (abstract available)
287. Degenhardt, L. & Hall, W. (2003). Patterns of co-morbidity between alcohol use and other substance use in the Australian population. Drug and Alcohol Review 22, 7-13. (abstract available)
288. Degenhardt, L. & Hall, W. (2006). Is cannabis use a contributory cause of psychosis? The Canadian Journal of Psychiatry 51, 556-565.
289. Degenhardt, L. & Hall, W. (2006). Canadian heroin supply and the Australian ‘heroin shortage’ (letter to the editor). Addiction 101, 1666-1668.
290. Degenhardt, L. & Hall, W. (2007). Cannabis-induced psychosis among Aboriginal Canadians of the Northwest Territories (letter to the editor). Canadian Journal of Psychiatry 52, 13-14.
291. Degenhardt, L. & Hall, W. (2007). The relationship between cannabis use and psychosis: Epidemiological evidence and biological plausibility. Advances in Schizophrenia and Clinical Psychiatry 3, 2-7.
292. Degenhardt, L., & Hall, W. (2008). Australian heroin seizures and the causes of the 2001 heroin shortage. International Journal of Drug Policy, 19(4), 293-294.
293. Degenhardt, L., & Hall, W. (2008). The adverse effects of cannabinoids: Implications for use of medical marijuana. Canadian Medical Association Journal, 178(13), 1685-1686.
294. Degenhardt, L. Hall, W., & Adelstein, B. (2001). Ambulance calls to suspected overdoses: New South Wales patterns July 1997 to June 1999. Australian and New Zealand Journal of Public Health 27, 447-450. (abstract available)
295. Degenhardt, L., Hall, C., Day, C., Dietze, P., Collins, L., & Pointer, S. (2005). Mapping the consequences of an unanticipated drug supply change of uncertain origins: Responses to the commentaries. Addiction 100, 930-932.
296. Degenhardt, L., Hall, W., & Lynskey, M. (2000). Cohort trends in the age of initiation of drug use in Australia. Australian and New Zealand Journal of Public Health 24, 421-426. (abstract available)
297. Degenhardt, L., Hall, W., & Lynskey, M. (2000). Cohort trends in the age of initiation of drug use in Australia. Australian and New Zealand Journal of Public Health 24, 421-426.
298. Degenhardt, L., Hall, W., & Lynskey, M. (2001). Ambulance calls to suspected overdoses: New South Wales patterns July 1997 to June 1999. Australian and New Zealand Journal of Public Health 25, 447-450.
299. Degenhardt, L., Hall, W., & Lynskey, M. (2001). The relationship between cannabis use and other substance use in the general population. Drug and Alcohol Dependence 64, 319-327. (abstract available)
300. Degenhardt, L., Hall, W., & Lynskey, M. (2001). Alcohol, cannabis and tobacco use among Australians: A comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. Addiction 96, 1603-1614. (abstract available)
301. Degenhardt, L., Hall, W., & Lynskey, M. (2001). Co-morbidity between alcohol, tobacco and cannabis use: Reply to David Ferguson (letter to the editor). Addiction 96, 1862.
302. Degenhardt, L., Hall, W., & Lynskey, M. (2001). The relationship between cannabis use and other substance use in the general population. Drug and Alcohol Dependence 64, 319-327.
303. Degenhardt, L., Hall, W., & Lynskey, M. (2001). The relationship between cannabis use, depression and anxiety among Australian adults: Findings from the National Survey of Mental Health and Well-Being. Social Psychiatry and Psychiatric Epidemiology 36, 219-227. (abstract available)
304. Degenhardt, L., Hall, W. & Lynskey, M. (2003). Testing hypotheses about the relationship between cannabis use and psychosis. Drug and Alcohol Dependence 71, 37-48. (abstract available)
305. Degenhardt, L., Hall, W. & Lynskey, M. (2003). Exploring the association between cannabis use and depression. Addiction 98, 1493-1504. (abstract available)
306. Degenhardt, L., Hall, W., Roxburgh, A., & Mattick, R.P. (2007). UK classification of cannabis: Is a change needed and why? The Lancet 370, 1541.
307. Degenhardt, L., Hall, W., & Warner-Smith, M. (2006). Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sexually Transmitted Infections 82, iii56-iii63.
308. Degenhardt, L., Kinner, S. A., Roxburgh, A., Black, E., Bruno, R., Fetherston, J., et al. (2008). Drug use and risk among regular injecting drug users in Australia: Does age make a difference? Drug and Alcohol Review, 27(4), 357-360.
309. Degenhardt, L., Knox, S., Barker, B., Britt, H., & Shakeshaft, A. (2005). The management of alcohol, tobacco and illicit drug use problems by general practitioners in Australia. Drug and Alcohol Review 24, 499-506.
310. Degenhardt, L., Lynskey, M., Coffey, C., & Patton, G. (2002). ‘Diagnostic orphans’ among young adult cannabis users: Persons who report dependence symptoms but do not meet diagnostic criteria. Drug and Alcohol Dependence 67, 205-212. (abstract available)
311. Degenhardt, L., Reuter, P., Collins, L. & Hall, W. (2005). Evaluating explanations of the Australian ‘heroin shortage’. Addiction 100, 459-469.
312. Degenhardt, L., Roxburgh, A. & Barker, B. (2005). Underlying causes of cocaine, amphetamine and opioid related deaths in Australia. Journal of Clinical Forensic Medicine 12, 187-195.
313. Degenhardt, L., Roxburgh, A., Black, E., Campbell, G., Bruno, R., & Kinner, S. (2008). The epidemiology of methamphetamine use and harm in Australia. Drug and Alcohol Review, 27(3), 243-252
314. Degenhardt, L., Roxburgh, A., & McKetin, R. (2007). Hospital separations for cannabis- and methamphetamine-related psychotic episodes in Australia. Medical Journal of Australia, 186, 342-345.
315. Degenhardt, L., Roxburgh, A., Van Beek, I, Hall, W.D., Robinson, M.K.F., Ross J., Mant, A. (2008). The effects of the market withdrawal of temazepam gel capsules on benzodiazepine injecting in Sydney, Australia. Drug and Alcohol Review, 27(2), 145-151.
316. Degenhardt, L., Tat Chiu, W., Sampson, N., Kessler, R.C., & Anthony, J.C. (2007). Epidemiological patterns of extra-medical drug use in the United States: Evidence from the National Comorbidity Survey Replication, 2001–2003. Drug and Alcohol Dependence 90, 210-223.
317. Degenhardt, L., Tennant, C., Gilmour, S., Schofield, D., Nash, L., Hall, W., & McKay, D. (2007). The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: Findings from a 10-month prospective study. Psychological Medicine 37, 927–934.
318. Degenhardt, L. & Topp, L. (2003). ‘Crystal meth’ use among polydrug users in Sydney’s dance party subculture: Characteristics, use patterns and associated harms. International Journal of Drug Policy 14, 17-24. (abstract available)
319. Degenhardt, L, Topp, L. & Day, C. (2003). Issues surrounding the detection of a reduction in drug supply: The heroin shortage in Australia in 2001. Bulletin On Narcotics Volume LV, Nos 1 and 2, 2003. The practice of drug abuse epidemiology. Vienna: United Nations Office on Drugs and Crime. (abstract available)
320. Dierker, L., He, J., Kalaydjian, A., Swendsen, J., Degenhardt, L., Glantz, M., Conway, K., Anthony, J., Chiu, W. T., Sampson, N. A., Kessler, R., & Merikangas, K. (2008). The Importance of Timing of Transitions for Risk of Regular Smoking and Nicotine Dependence. Annals of Behavioral Medicine, 1-6.
321. Digiusto, E., Lintzeris, N., Breen, C., Kimber, J., Mattick. R.P., Bell, J., Ali, R., & Saunders, J.B. (2005). Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. Addictive Behaviours 30, 443-456.
322. Digiusto, E., Mattick, R.P., Kimber, J., O’Brien, S., Doran, C., Henderson, N., & Breen, C. (2001). National evaluation of pharmacotherapies for opioid dependence – why have we done it? (Editorial). Drug and Alcohol Review 20, 139-141.
323. Digiusto, E., Panjari, M., Gibson, A., Rea, F., & NEPOD Research Group. (2006). Follow-up difficulty: Correlates and relationship with outcome in heroin dependence treatment in the NEPOD study. Addictive Behaviors 31, 1201-1210.
324. Digiusto, E., Shakeshaft, Mattick, R.P., & NEPOD Research Group. (2006). Effects of pharmacotherapies for opioid dependence on participants' criminal behaviour and expenditure on illicit drugs: An Australian National Evaluation (NEPOD). Australian and New Zealand Journal of Criminology 39, 171-189.
325. Digiusto, E., Shakeshaft, A.P., Ritter A., O’Brien, S., Mattick, R.P., & NEPOD Research Group. (2004). Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction 99, 450-460.
326. Dillon, P. (2005). Over The Influence, The Harm Reduction Guide for Managing Drugs and Alcohol (book review). Drug and Alcohol Review 24, 290-291.
327. Dillon, P. (1998). Proactive or sensationalist?: The media and harm reduction. International Journal of Drug Policy 9, 175-179. (abstract available)
328. Dillon, P., Copeland, J. & Jansen, K. (2003). Patterns of use and harms associated with non-medical ketamine use. Drug and Alcohol Dependence 69, 23-28. (abstract available)
329. Dillon, P., Copeland, J. & Peters, R. (1999). Exploring the relationship between male homo/bisexuality, body image and steroid use. Culture, Health and Sexuality 1, 317-327. (abstract available)
330. Dillon, P. & Degenhardt, L. (2001). Ketamine and GHB: New trends in club drug use? Journal of Substance Use 6, 11-15. (abstract available)
331. Dillon, P., Goldspink-Lord, L., & Parkhill, N. (1996). Sex, drugs and just say no: A media perspective. International Journal of Drug Policy 7, 183-186. (abstract available)
332. Dillon, P., & Singleton, M. (1996). Anabolic Steroids. Policing Issues and Practice Journal 4, 24-31.
333. Dillon, P. & Singleton, M. (1999). Cannabis. Policing Issues and Practice Journal 7, 1- 9.
334. Dolan, K. (1989). HIV and AIDS - Intravenous drug use in New South Wales, Australia. International Journal of Drug Policy 1, 22-26.
335. Dolan, K. (1991). Testing saliva for HIV. International Jounal of Drug Policy 2, 3.
336. Dolan, K. (1993). Drug injectors in prison and the community in England. International Journal of Drug Policy 4, 179-183.
337. Dolan, K. (1994). Sex in the Slammer. National AIDS Bulletin 8, 12-13.
338. Dolan, K. (1997). AIDS, drugs and risk behaviour in prison: State of the art. International Journal of Drug Policy 8, 5-17.
339. Dolan, K. (1997/98). Evidence about HIV transmission in prisons. Canadian HIV/AIDS Policy & Law Newsletter, 3/4, 32-35.
340. Dolan, K. (1999). Injecting rooms in Switzerland. NSW Public Health Bulletin 10, 59-60.
341. Dolan, K. (2001). Can hepatitis C transmission be reduced in Australian prisons? Medical Journal of Australia 174, 378-379.
342. Dolan, K., Clement, N., Rouen, D., Rees, V., Shearer, J., & Wodak, A. (2004). Can drug injectors be encouraged to adopt non-injecting routes of administration (NIROA) for drugs? Drug and Alcohol Review 23, 281-286.
343. Dolan, K., Donoghoe, M. & Stimson, G.V. (1990). Drug injecting and syringe sharing in custody and the community: An exploratory survey of HIV risk behaviour. The Howard Journal of Criminal Justice 29, 177-186.
344. Dolan, K.A., Hall, W., & Wodak, A. (1996). Methadone maintenance reduces injecting in prison. British Medical Journal 312, 1162.
345. Dolan, K., Hall, W., Wodak, A., & Gaughwin, M. (1994). Evidence of HIV transmission in an Australian prison (A letter to the editor). Medical Journal of Australia 160, 734.
346. Dolan, K., Kimber, J., Fry, C., Fitzgerald, J., McDonald, D., & Trautmann, F. (2000). Drug consumption facilities in Europe and the establishment of supervised injecting centres in Australia, Drug and Alcohol Review 19, 337-346. (abstract available)
347. Dolan, K., Kite, B., Black, E. Aceijas, C., Stimson, G.V. for the Reference Group on HIV/AIDS Prevention and Care among Injecting Drug Users in Developing and Transitional Countries. (2007). HIV in prison in low-income and middle-income countries. Lancet 7, 32-41.
348. Dolan, K. & Larney, S. (2007). HIV in prison in Asia and the Pacific. Development Bulletin 69, 72-74.
349. Dolan, K., Lowe, D. & Shearer, J. (2004). Evaluation of the condom distribution program in NSW prisons, Australia. Journal of Law, Medicine and Ethics 32, 124-128.
350. Dolan, K. MacDonald, M. & Silins, E. (2005). Needle and syringe programs: A review of the evidence. Canberra: Australian Government Department of Health and Ageing.
351. Dolan, K., Murdo, B. & White, B. (2004). HIV education in a Siberian prison colony for drug dependent males. International Journal for Equity in Health 3, 3-7.
352. Dolan, K. & Niven, H. (2005). A review of HIV prevention among young injecting drug users: A guide for researchers. Harm Reduction Journal 2:5.
353. Dolan, K. & Rouen, D. (2003). Evaluation of an educational comic on harm reduction for prison inmates in New South Wales. International Journal of Forensic Psychology 1, 138-141.
354. Dolan, K., Rouen, D. & Kimber, J. (2004). An overview of the use of urine, hair, sweat and saliva to detect drug use. Drug and Alcohol Review 23, 213-217.
355. Dolan, K., Rutter, S. & Wodak, A. (2003). Prison-based syringe exchange programmes: A review of international research and development. Addiction 98, 153-158. (abstract available)
356. Dolan, K., Rutter, S., Wodak, A., Hall, W., Maher, L., & Dixon, D. (1996). Is syringe exchange feasible in a prison setting? Medical Journal of Australia 164, 508.
357. Dolan, K., Shearer, J., MacDonald, M., Mattick, R.P., Hall, W., & Wodak, A.D. (2003). A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug and Alcohol Dependence 72, 59-65. (abstract available)
358. Dolan, K., Shearer, J., White, B., Zhou, J., Kaldor, J., & Wodak, A. (2005). Four-year follow-up of imprisoned male heroin users and methadone treatment: Mortality, re-incarceration and hepatitis C infection. Addiction 100, 820-828.
359. Dolan, K. & Silins, E. (2005). Needle and syringe programs: Your questions answered. Canberra: Australian Government Department of Health and Ageing.
360. Dolan, K.A., Stimson, G.V., & Donoghoe, M.C. (1993). Reductions in HIV risk behaviour and stable HIV prevalence in syringe-exchange clients and other injectors in England. Drug and Alcohol Review 12, 133-42.
361. Dolan, K. & Wodak, A. (1996). An international review of methadone provision in prisons. Addictions Research 4, 85-97.
362. Dolan, K. & Wodak, A. (1999). HIV transmission in a prison system in an Australian state. Medical Journal of Australia 171, 14-17. (abstract available)
363. Dolan, K., Wodak, A., & Hall, W. (1998) Methadone maintenance treatment reduces heroin injection in New South Wales prisons. Drug and Alcohol Review 17, 153-158.
364. Dolan, K., Wodak, A. & Hall, W. (1998). A bleach program for inmates in NSW: An HIV prevention strategy. Australian and New Zealand Journal of Public Health 22, 838-840.
365. Dolan, K., Wodak, A. & Hall, W. (1999). HIV risk behaviour and prevention in prison: A bleach programme for inmates in NSW. Drug and Alcohol Review 18, 139-144. (abstract available)
366. Dolan K, Wodak A, Hall, Gaughwin M & Rae F. (1996). Risk behaviour of IDUs before, during and after imprisonment in NSW. Addiction Research 4, 151-60.
367. Dolan, K., Wodak, A., Hall., Gaughwin, M & Rae, F. (1996). La Trasmissione dell'infezione da HIV in Carcere. Limitazione del Danno Suppl. ad ASPE 8, 15-19.
368. Dolan, K., Wodak, A., Hall, W., & Kaplan, E. (1998). A mathematical model of HIV transmission in NSW prisons. Drug and Alcohol Dependence 50, 197-202.
369. Dolan, K.A., Wodak, A.D., & Rutter, S.A. (1996). Is syringe exchange feasible in a prison setting ? [letter to the editor (reply)]. Medical Journal of Australia 165, 59.
370. Dolan, K., Wodak, A., & Penny, R. (1995). AIDS behind bars: Preventing HIV spread among incarcerated drug injectors. AIDS 9, 825-832.
371. Donnelly, N., Hall, W., & Christie, P. (1995). The effects of decriminalisation on cannabis use in South Australia 1985-1993. Australian Journal of Public Health 19, 281-287. (abstract available)
372. Donnelly, N., Hall, W., & Christie, P. (2000). Effects of the Cannabis Expiation Notice System on the prevalence of cannabis use in South Australia: Evidence from the National Drug Strategy Household surveys 1985-1995. Drug and Alcohol Review 19, 265-269.
373. Donnelly, N., McManus, P., Dudley, J., & Hall, W. (2000). Impact of increasing the re-supply interval on the seasonality of subscribed prescription use in Australia. Australian and New Zealand Journal of Public Health 24, 503-506.
374. Donoghoe, M,, Dolan, K.A. & Stimson, G.V. (1992). Lifestyle factors and social circumstances of syringe sharing in injecting drug users. British Journal of Addiction 87, 993-1003.
375. Donoghoe, M,, Stimson, G.V. & Dolan, K. (1989). Sexual behaviour of injecting drug users and associated risks of HIV infection for non- injecting sexual partners. AIDS Care 1, 51-58.
376. Donoghoe, M,, Stimson, G.V,, Dolan, K., & Alldritt, L. (1989). Changes in HIV risk behaviour in clients of syringe exchange schemes in England and Scotland. AIDS 3, 267-272.
377. Doran, C. M. (2008). Economic evaluation of interventions to treat opiate dependence: A review of the evidence. PharmacoEconomics, 26(5), 371-393.
378. Doran, C. M., & Shakeshaft, A. P. (2008). Using taxes to curb drinking in Australia. Lancet, 372(9640), 701-702.
379. Doran, C. M., Duszynski, K. M., Beilby, J. J., & Mattick, R. P. (2006). Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practice. Addictive Behaviors, 31(11), 1947-1958.
380. Doran, C., Fawcett, J., Shakeshaft, A., Shanahan, M., & Mattick, R.P. (2003). New Pharmacotherapies for alcohol dependence: are they being used and what do they cost? Medical Journal of Australia 179, 218.
381. Doran, C. Gascoigne, M., Shakeshaft, A., & Petrie, D. (2006). The consumption of alcohol by Australian adolescents: A comparison of revenue and expenditure. Addictive Behaviours 31, 1919-1928.
382. Doran, C., Shakeshaft, A. & Fawcett, J. (2004). General practitioners' role in preventive medicine: Scenario analysis using alcohol as a case study. Drug and Alcohol Review 23, 399-404.
383. Doran, C.M., Shakeshaft, A.P., Gates, J., Fawcett, J.E., & Mattick, R.P. (2002). Current prescribing patterns of bupropion in Australia (Letter). Medical Journal of Australia 177, 162.
384. Doran, C., Shanahan, M., Bell, J., & Gibson, A. (2004). A cost-effectiveness analysis of buprenorphine-assisted heroin withdrawal. Drug and Alcohol Review 23, 171-175.
385. Doran, C., Shanahan, M., Digiusto, E., O'Brien, S., Mattick, R.P. & the NEPOD Research Group (2006). Cost-effectiveness analysis of maintenance agonist treatments in the NEPOD. Expert Review Pharmacotherapies Outcomes Research 6, 437-446.
386. Doran, C., Shanahan, M., Mattick, R.P., Ali, R., White, J., & Bell, J. (2003). Buprenorphine versus methadone maintenance: A cost effectiveness analysis. Drug and Alcohol Dependence 71, 295-302. (abstract available)
387. Doran, C., Stafford, J., Shanahan, M., & Mattick, R. P. (2007). Characteristics of Australian smokers using bupropion and nicotine-replacement therapies. Expert Review of Pharmacoeconomics and Outcomes Research, 7(1), 41-47.
388. Doran, C. Valenti, L., Robinson, M., Britt, H., & Mattick, R.P. (2006). Smoking status of Australian general practice patients and their attempts to quit. Addictive Behaviours 31, 758-766.
389. Dunlap, E., Johnson, B.D., Manwar, A., & Maher, L. (1997). Female crack dealers in New York City: Who they are and what they do? Women and Criminal Justice 8, 25-55.
390. Dzialdowski, A., Heather, N., & Crawford, J. (1988). Perceptions of drinkers and abstainers in a sample of Scottish adults. Alcohol and Alcoholism 23, 7-16.
391. Edwards, G., Babor, T., West, R., & Hall, W. (2002). Another mirror shattered: industry origins of a book which claims that nicotine is not addictive. Addiction 97, 1-5.
392. Edwards, G., West, R., Babor, T., & Hall, W. (2001). No switching off the camera: How Addiction will respond to infringements of ethical publishing expectation. Addiction 96, 1391-1392.
393. Edwards, P., Wodak, A., Cooper, D.A., Thompson, I.L., & Penny, R. (1990). The gastroenterological manifestation of AIDS. Australian and New Zealand Journal of Medicine 20, 141-148.
394. Elkins, L. & Richmond, R. (1990). Control can go up in smoke. Diabetes Conquest Spring, 6-9.
395. Farrell, M. & Hall, W. (1998). The Swiss Heroin Trials: Testing alternative approaches. British Medical Journal 316, 639.
396. Farrell, M., Ward, J., Mattick, R., Hall, W., Stimson, G., des Jarlais, D., Gossop, M., & Strang, J. (1994). Methadone maintenance treatment in opiate dependence: A review. British Medical Journal 309, 997-1001.
397. Fawcett, J., Shakeshaft, A.P., Harris, M.F., Wodak, A., Mattick, R.P., & Richmond, R.L. (2004). Using AUDIT to classify patients into Australian Alcohol Guideline categories. Medical Journal of Australia 180, 598.
398. Finney Lamb, C. E., Boers, M., Owens, A., Copeland, J., & Sultana, T. (2008). Exploring experiences and attitudes about health care complaints among pregnant women, mothers and staff at an Opioid Treatment Service. Australian health review : A publication of the Australian Hospital Association, 32(1), 66-75.
399. Flaherty, B., Homel, P., & Hall, W. (1991). Public attitudes towards alcohol control policies. Australian Journal of Public Health 15, 301-306.
400. Freeman, A., Jones, C.G.A., Weatherburn, D.J., Rutter, S., Spooner, C.J., & Donnelly, N. (2005). The impact of the Sydney Medically Supervised Injecting Centre (MSIC) on crime. Drug and Alcohol Review 24, 173-184.
401. Friedman, S.R, De Jong, W., & Wodak, A. (1993). Community development as a response to HIV among drug injectors. AIDS 7(suppl 1), S263-S269.
402. Gallagher, J. & Teesson, M. (2000). Measuring disability, need and outcome in Australian community mental health services. Australian and New Zealand Journal of Psychiatry 34, 850-855.
403. Gaston, J. E., & Vogl, L. (2005). Psychometric properties of the General Well-Being Index. Quality of Life Research, 14(1), 71-75.
404. Gates, P., Copeland, J., Stevenson, R. & Dillon, P. (2007). The influence of product packaging on young people’s ratings of alcohol palatability. Alcohol & Alcoholism 42, 138-142.
405. Gates, J., Post, J., Kaldor, J., Pan, Y., Haber, P., Lloyd, A., Dolan, K., & Hepatitis C Incidence and Transmission in Prison Study Group (2004). Risk factors for hepatitis C infection and perception of antibody status among male prison inmates in the Hepatitis C Incidence and Transmission in Prisons Study cohort, Australia. Journal of Urban Health 81, 448-452.
406. Gaughwin, M., Kliewer, E., Ali, R., Faulkner, C., & Wodak, A. (1993). The prescription of methadone for opiate dependence in Australia, 1985-1991. Medical Journal of Australia 159, 107-108.
407. Gibson, A. (2003). A comparison of buprenorphine treatment in clinic and primary care settings: A randomised trial (In Reply). Medical Journal of Australia 179, 558.
408. Gibson, A., Day, C., & Degenhardt, L. (2005). The impact of illicit drug market changes on health agency operations in Sydney, Australia. Journal of Substance Abuse Treatment 28, 35-40.
409. Gibson, A. & Degenhardt, L. (2007). Mortality related to pharmacotherapies for opioid dependence: A comparative analysis of coronial records. Drug and Alcohol Review 26, 405 – 410.
410. Gibson, A., Degenhardt, L., Day, C., & McKetin, R. (2005). Recent trends in heroin supply to markets in Australia, the United States and Western Europe. International Journal of Drug Policy 16, 193-299.
411. Gibson, A., Degenhardt, L. & Hall, W. (2007). Opioid overdose deaths can occur in patients with naltrexone implants. Medical Journal of Australia 186, 152-153.
412. Gibson, A., Degenhardt, L. & Hall, W. (2007). Opioid overdose deaths can occur in patients with naltrexone implants (In Reply). Medical Journal of Australia 187, 56-57.
413. Gibson, A., Doran, C.M., Bell, J., Ryan, A., & Lintzeris, N. (2003). A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. Medical Journal of Australia 179, 38-42. (abstract available)
414. Gibson, A., Degenhardt, L., Mattick, R. P., Ali, R., White, J., & O'Brien, S. (2008). Exposure to opioid maintenance treatment reduces long-term mortality. Addiction, 103, 462-468.
415. Gibson, A. & Shanahan, M. (2007). Costs and outcomes of treatments for excessive alcohol consumption: Making policy decisions with the available data. Drugs - Education Prevention and Policy 14, 1-17.
416. Gilmour, S., Degenhardt, L., Hall, W., & Day, C. (2006). Using intervention time series analyses to assess the effects of imperfectly identifiable natural events: A general method and example. BMC Medical Research Methodology, 6,16.
417. Gilmour, S., Koch, I., Degenhardt, L., & Day, C. (2006). Identification and quantification of change in Australian illicit drug markets. BMC Public Health 6,200.
418. Gomel, M., Oldenburg, B., Lemon, J., Owen, N., & Westbrook, F. (1993). Pilot study of the effects of a workplace smoking ban on indices of smoking, cigarette craving, stress and other health behaviours. Psychology and Health 8, 223-229.
419. Gossop, M., Darke, S., Griffiths, P., Hando, J., Powis, B., Hall, W., & Strang, J. (1995). The Severity of Dependence Scale (SDS) in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90, 607-614.
420. Grabowski, J., Shearer, J., Merrill, J., & Stevens Negus, S. (2004). Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addictive Behaviours 29, 1439-1464.
421. Greeley, J. (1989). Pavlovian conditioning and pain regulation: Insights from pharmacological conditioning with morphine and naloxone. Biological Psychology 28, 41-65.
422. Greeley, J. (1992). The nature of opioid dependence (Editoral). Australian Journal of Psychopharmacology 6, 1.
423. Greeley, J., Le A.D., Poulos, C.X., & Cappell, H. (1988). Paradoxical analgesia induced by naloxone and naltrexone. Psychopharmacology 96, 36-39.
424. Greeley, J., Swift, W., & Heather, N. (1992). Depressed affect as a predictor of increased desire for alcohol in current drinkers of alcohol. British Journal of Addiction 87, 1005-1012.
425. Greeley, J., Swift, W., & Heather, N. (1993). To drink or not to drink?: Assessing conflicting desires in dependent drinkers in treatment. Drug & Alcohol Dependence 32, 169-179.
426. Greeley, J., Swift, W., Prescott, J., & Heather, N. (1993). Reactivity to alcohol-related cues in heavy and light drinkers. Journal of Studies on Alcohol 54, 359-368.
427. Greeley, J. & Westbrook, R.F. (1990). Some effects of exposure to a heat stressor upon the rat’s subsequent reactions to that stressor. Quarterly Journal of Experimental Psychology 42B, 241-265.
428. Grenyer, B.F.S., Williams, G., Swift, W., & Neill, O. (1992). The prevalence of social-evaluative anxiety in opioid users seeking treatment. International Journal of the Addictions 27, 665-673.
429. Griffiths, P. & McKetin, R. (2003). Developing a global perspective on drug consumption patterns and trends – the challenge for drug epidemiology. In Bulletin On Narcotics Volume LV, Nos 1 and 2, 2003. The practice of drug abuse epidemiology. Vienna: United Nations Office on Drugs and Crime. (abstract available)
430. Guinan, J.J., Darke, S., & Gold, J. (1990). The epidemiology of HIV infection and risk behaviour of intravenous drug users: A reply to Donovan et al. (letter to the editor). Medical Journal of Australia 152, 499.
431. Guinan, J.J., Hall, W., Clarke, J.C., & Gold, J. (1992). Alcohol and recreational drug use by HIV-seropositive homosexual men. Drug and Alcohol Review 11, 355-362.
432. Gureje, O., Degenhardt, L., Olley, B., Uwakwee, R., Udofiaf, O., Wakil, A., Adeyemi, O., Bohnert, K.M., & Anthony, J.C. (2007). A descriptive pidemiology of substance use and substance use disorders in Nigeria during the early 21st century. Drug and Alcohol Dependence 91, 1-9.
433. Haber, P.S., Wilson, J.S., Apte, M.V., Hall, W., & Goumas, K. (1994). Lipid intolerance does not account for susceptibility to alcoholic and gallstone pancreatitis. Gastroenterology 106, 742-748.
434. Haber, P. S., Cameron, B., Elliott, L., Teutsch, S., Ffrench, R., Dolan, K., et al. (2007). Correlates of incident HCV infection and seronegative-immune status in high risk, IDU prisoners. Hepatology, 46, 630A-630A.
435. Haber, P.S., Wilson, J.S., McGarity, B.M., Hall, W., Thomas, M.C., & Pirola, R.C. (1991). Alpha-1-antitrypsin phenotypes and alcoholic pancreatitis. Gut 32, 945-948.
436. Hall, W. (1992). The Australian debate about the legalisation of heroin and other illicit drugs. Journal of Drug Issues 22, 563-577.
437. Hall, W. (1993). Perfectionism in the therapeutic appraisal of methadone maintenance. Addiction 88, 1181-1182.
438. Hall, W. (1994). Value for money in addiction services. Addiction 89, 919-923.
439. Hall, W. (1994). The health and psychological effects of cannabis use. Current Issues in Criminal Justice 6, 208-220.
440. Hall, W. (1995). The public health implications of cannabis use. Australian Journal of Public Health 19, 235-242.
441. Hall, W. (1995). What advice should family physicians give their patients about the health effects of cannabis? Australian Family Physician 24, 1237-1240.
442. Hall, W. (1995). Making research more relevant to practice. Drug and Alcohol Review 14, 149-150.
443. Hall, W. (1995). Variations in prohibition: Harm minimisation in Australia and Drug Wars in the USA. Australian and New Zealand Journal of Criminology, Special Supplementary Issue, 74-77.
444. Hall, W. (1996). How can we reduce the number of heroin "overdose" deaths? Medical Journal of Australia 164, 197-198.
445. Hall, W. (1996). Changes in the public perceptions of the health benefits of alcohol use, 1989 to1994. Australian Journal of Public Health 20, 93-95.
446. Hall, W. (1996). Statistical questions. A commentary on Finney et al.'s "the effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects". Addiction 91, 1808.
447. Hall, W. (1996). What have population surveys revealed about substance use disorders and their co-morbidity with other mental disorders? Drug and Alcohol Review 15, 157-170.
448. Hall, W. (1996). Methadone maintenance treatment as a crime control measure. Crime and Justice Bulletin Number 29, June, 1-12.
449. Hall, W. (1997). Marijuana myths, marijuana fact (book review). Science 278, 75.
450. Hall, W. (1997). The recent Australian debate about the prohibition on cannabis use. Addiction 92, 1109-1115.
451. Hall, W. (1997). Highs and lows. Lancet 350, (suppl. III): 1.
452. Hall, W. (1997). The search for an elixir of abstinence. Australian Family Physician 27, S1-S2.
453. Hall, W. (1997). Australia: La nuova sfida e l'overdose. Aspe Disagio Pace Ambiente 16, 6-7.
454. Hall, W. (1997). The role of legal coercion in the treatment of offenders with alcohol and heroin problems. Australian and New Zealand Journal of Criminology 30, 103-120.
455. Hall, W. (1997). Addiction: Highs and lows. Review 1997. Supplement to Lancet December, 20-27.
456. Hall, W. (1997). An ongoing debate. Science 278, 75.
457. Hall, W. (1998). Creating space for a more reasoned debate about drug policy. Policy Options 19, 18-21.
458. Hall, W. (1998). Cannabis and psychosis. Drug and Alcohol Review, 17, 433-444.
459. Hall, W. (1998). The respiratory risks of cannabis smoking. Addiction 93, 1461-1463.
460. Hall, W. (1998). The search for an elixir of abstinence. Australian Family Physician 27, S1-S2.
461. Hall, W. (1999). Patient matching in the treatment of alcohol dependence: Is the null hypothesis still alive and well? Addiction 94, 52-54.
462. Hall, W. (1999) Reducing the toll of opioid overdose deaths in Australia. Drug and Alcohol Review 18, 213-220.
463. Hall, W. (1999) Appraisals of the health effects of cannabis: Ideology and evidence. FAS Drug Policy Analysis Bulletin 7 June, 270.
464. Hall, W. (1999). Opium in Britain: Conflicting and converging interests. Lancet 353, 1449-1450.
465. Hall, W. (1999). Appraisals of the health effects of cannabis: Ideology and evidence. FAS Drug Policy Analysis Bulletin June, Number 7.
466. Hall, W. (2000) Transcending methadone. Lancet 355, 585.
467. Hall, W. (2000) Rolleston revisited. Addiction 95, 1273-1274.
468. Hall, W. (2000) UROD: An Antipodean therapeutic enthusiasm. Addiction 95, 1765-1766.
469. Hall, W. (2000). The cannabis policy debate: Finding a way forward. Canadian Medical Association Journal 162, 1690-1692.
470. Hall, W. (2001). Reducing the harms of cannabis use: The policy debate in Australia. Drug and Alcohol Dependence 62, 163-174.
471. Hall, W. & Babor, T. (2000) Cannabis and public health: assessing the burden. Addiction 95, 485-490.
472. Hall, W., Bell, J., & Carless, J. (1993). Crime and drug use among applicants for methadone maintenance. Drug and Alcohol Dependence 31, 123-129.
473. Hall, W., Carless, J., Homel, P., Flaherty, B., & Reilly, C. (1991). The characteristics of cocaine users among young Sydney adults. Medical Journal of Australia 155, 11-13.
474. Hall, W., Chen, R., & Evans, B. (1995). Characteristics of clients admitted to the Buttery, a therapeutic community, 1980-1992. Drug and Alcohol Review 14, 125-129.
475. Hall, W. & Darke, S. (1997). Prima i vecchi. Aspe Disagio Pace Ambiente 16, 8-10.
476. Hall, W. & Darke, S. (1998). Trends in opiate overdose deaths in Australia 1979-1995. Drug and Alcohol Dependence 52, 71-77.
477. Hall, W., Darke, S., Ross, M., & Wodak, A. (1993). Patterns of drug use and risk-taking among opioid and amphetamine injecting drug users in Sydney. Addiction 88, 509-516.
478. Hall, W. & Degenhardt, L. (1998). The decline in alcohol disorders with age: Causes and implications. Australasian Journal of Ageing 17, 158-159.
479. Hall, W. & Degenhardt, L. (2000). Cannabis and psychosis. Australian and New Zealand Journal of Psychiatry 34, 26-34. (abstract available)
480. Hall, W. & Degenhardt, L. (2003). Medical marijuana initiatives. Are they justified? How successful are they likely to be? CNS Drugs 17, 689-697. (abstract available)
481. Hall, W. & Degenhardt, L. (2003). Marijuana for medical purposes. New Ethical Journal December, 9-15.
482. Hall, W. & Degenhardt, L. (2006). What are the policy implications of the evidence on cannabis and psychosis? The Canadian Journal of Psychiatry 51, 566-574.
483. Hall, W. & Degenhardt, L. (2007). Prevalence and correlates of cannabis use in developed and developing countries. Current Opinion in Psychiatry 20, 393–397.
484. Hall, W., & Degenhardt, L. (2007). Regulating opioid prescribing to provide access to effective treatment while minimizing diversion: An overdue topic for research. Addiction, 102, 1685-1688.
485. Hall, W., & Degenhardt, L. (2008). Cannabis use and the risk of developing a psychotic disorder. World Psychiatry, 7(2), 68-71.
486. Hall, W., Degenhardt, L., & Currow, D. (2001). Allowing the medical use of cannabis. Medical Journal of Australia 175, 39-40.
487. Hall, W., Degenhardt, L., Gibson, A., & Mattick, R. P. (2008). Response to Degenhardt et al.: 'Depot naltrexone use for opioid dependence in Australia: Large-scale use of an unregistered medication in the absence of data on safety and efficacy'. Drug and Alcohol Review, 27(4), 448-449.
488. Hall, W., Degenhardt, L. & Lynskey, M. (1999). Opioid overdose mortality in Australia, 1964-1997: Birth-cohort trends. Medical Journal of Australia 171, 34-37. (abstract available)
489. Hall, W., Degenhardt, L. & Lynskey, M. (1999). Cohort trends in overdose mortality in Australia 1964-1966: A window on post-war trends in heroin use. Medical Journal of Australia 171, 34-37.
490. Hall, W., Degenhardt, L., & Lynskey, M. (2000). Trends in methadone overdose death in Australia and the United Kingdom 1985-1995. Drug and Alcohol Dependence 57, 247-254.
491. Hall, W., Degenhardt, L. & Teesson, M. (2004). Cannabis use and psychotic disorders: An update. Drug and Alcohol Review 23, 433-443.
492. Hall, W. & Dolan, K. (1996). Is there a role for contact tracing in preventing HIV transmission among drug users? Editorial. Addiction 91, 917-919.
493. Hall, W. & Farrell, M. (1997). Comorbidity of mental disorders with substance misuse. British Journal of Psychiatry 171, 4-5.
494. Hall, W., Flaherty, B., & Homel, P. (1992). Public perceptions of the risks and benefits of alcohol use. Australian Journal of Public Health 16, 38-42.
495. Hall, W. & Hando, J. (1993). Illicit amphetamine use as a public health problem in Australia. Medical Journal of Australia 159, 643-644.
496. Hall, W. & Hando, J. (1994). Route of administration and adverse effects of amphetamine use among young adults in Sydney, Australia. Drug and Alcohol Review 13, 277-284.
497. Hall, W., Hando, J., Darke, S., & Ross, J. (1996). Psychological morbidity and route of administration among amphetamine users in Sydney, Australia. Addiction 91, 81-87.
498. Hall, W. & Heather, N. (1991). Issue of statistical power in comparative evaluations of minimal and intensive controlled drinking interventions. Addictive Behaviours 16, 83-87.
499. Hall, W., Hunter, E., & Spargo, R. (1993). Alcohol-related problems among a population sample of Aboriginal drinkers in the Kimberley region of Western Australia. Addiction 88, 1091-1100.
500. Hall, W., Hunter, E.M., & Spargo, R. (1994). Alcohol use and incarceration in a police lockup among Aboriginals in the Kimberley Region of Western Australia. Australian and New Zealand Journal of Criminology 27, 57-73.
501. Hall, W., Kimber, J., & Lynskey, M. (2001). Breaking the deadlock over an Australian trial of injectable opioid maintenance. Medical Journal of Australia 176, 72-73.
502. Hall, W., Lynskey, M., & Degenhardt, L. (2000). Trends in opiate-related deaths in the United Kingdom and Australia, 1985-1995. Drug and Alcohol Dependence 57, 247-254. (abstract available)
503. Hall, W. & Mant, A. (1996). Harm reduction as a focus for research. Drug and Alcohol Review 15, 5-6.
504. Hall, W. & Mattick, R. (1997). Ultrarapid opiate detoxification. Medical Journal of Australia 176, 393-396.
505. Hall, W. & Mattick, R.P. (2000). Is ultra-rapid opioid detoxification a viable option in the treatment of opioid dependence? CNS Drugs 14, 251-255. (abstract available)
506. Hall, W. & Mattick, R. P. (2007). Clinical update: Codeine maintenance in opioid dependence. Lancet, 370, 550-552.
507. Hall, W., & Mattick, R. P. (2008). Oral substitution treatments for opioid dependence. Lancet, 371(9631), 2150-2151.
508. Hall, W., Mattick, R., Saunders, J.B., & Wodak, A. (1997). Rapid opiate detoxification treatment. (Editorial) Drug and Alcohol Review 16, 325-328.
509. Hall, W. & Nelson, J. (1996). Correlates of the perceived health risks of marijuana among Australian adults. Drug and Alcohol Review 15, 137-144.
510. Hall, W., Ross, J., Lynskey, M., Law, M., & Degenhardt, L. (2000). How many dependent heroin users are there in Australia? Medical Journal of Australia, 528-531.
511. Hall, W. & Sannibale, C. (1996). Are there two types of alcoholism? Lancet 348, 1258.
512. Hall, W., Saunders, J., Babor, T., Aasland, O.G., Amundsen, A., Hodgson, R., & Grant, M. (1993). The structure and correlates of alcohol dependence: WHO Collaborative Project on Early Detection of Person with Harmful Alcohol Consumption - III. Addiction 88, 1627-1636.
513. Hall, W. & Solowij, N. (1996). Steering a course between the Charybdis of credulity and the Scylla of scepticism. Addiction 91, 770-773.
514. Hall, W. & Solowij, N. (1997). Long-term cannabis use and mental health (Editorial). British Journal of Psychiatry 171, 107-108.
515. Hall, W. & Solowij, N. (1998). Adverse effects of cannabis. Lancet 352, 1611-1616.
516. Hall, W., Solowij, N., & Lemon, J. (1996). A Summary of "The Health and Psychological Effects of Cannabis". Addiction 91, 759-762.
517. Hall, W. & Swift, W. (2000). The THC content of cannabis in Australia: Evidence and implications. Australian and New Zealand Journal of Public Health 24, 503-508. (abstract available)
518. Hall, W., Teesson, M., Lynskey, M. & Degenhardt, L. (1999). The 12-month prevalence of substance use and ICD-10 substance use disorders in Australian adults: Findings from the National Survey of Mental Health and Well-Being. Addiction 94, 1541-1550.
519. Hall, W., Ward, J., Mattick, R.P. (1993). Methadone maintenance treatment in prisons: The New South Wales experience. Drug and Alcohol Review 12, 193-203. Also reprinted in Psychiatry, Psychology & Law, 1, 33-44 (1994).
520. Hall, W. & Wodak, A. (1999). Is naltrexone a cure for heroin dependence? (Editorial). Medical Journal of Australia 171, 9-10.
521. Hall, W. & Zador, D. (1997). The alcohol withdrawal syndrome. Lancet 349, 1897-1900.
522. Hall, W. & Zador, D. (2000) Challenge of reducing drug-related deaths. Lancet 356, 7.
523. Hando, J., Darke, S., O'Brien, S., Maher, L., & Hall, W. (1998). The development of an early warning system to detect trends in illicit drug use in Australia: The Illicit Drug Reporting System. Addiction Research 6, 97-113.
524. Hando, J., Flaherty, B., & Rutter, S. (1997). An Australian profile on the use of cocaine. Addiction 92, 173-182.
525. Hando, J. & Hall, W. (1994). HIV risk-taking behaviour among amphetamine users in Sydney, Australia. Addiction 89, 79-85.
526. Hando, J., Howard, J., & Zibbert, E. (1997). Risky drug practices and treatment needs of youth detained in New South Wales Juvenile Justice Centres. Drug and Alcohol Review 16, 137-145.
527. Hando, J., Topp, L., & Hall, W. (1997). Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug and Alcohol Dependence 46, 105-113.
528. Harvey, E., Shakeshaft, A., Hetherington, K., Sannibale, C., & Mattick, R.P. (2007). The efficacy of diversion and aftercare strategies for adult drug-involved offenders: A summary and methodological review of the outcome literature. Drug and Alcohol Review 26, 379-387.
529. Havard, A., Teesson, M., Darke, S., Ross, J. (2006). Depression among heroin users: 12 month outcomes from the Australian Treatment Outcome Study (ATOS). Journal of Substance Abuse and Treatment 30, 355-362.
530. Havard, A., Shakeshaft, A., & Sanson-Fisher, R. (2008). Systematic review and meta-analyses of strategies targeting alcohol problems in emergency departments: Interventions reduce alcohol-related injuries. Addiction, 103, 368-376.
531. Hawkins, N. G., Shakeshaft, A., & Sanson-Fisher, R. W. (2006). A community-based attempt to reduce alcohol-related harms in rural New South Wales. Alcoholism-Clinical and Experimental Research, 30(9), 180A-180A.
532. Hawkins, N. G., Sanson-Fisher, R. W., Shakeshaft, A., D'Este, C., & Green, L. W. (2007). The multiple baseline design for evaluating population-based research. American Journal of Preventive Medicine, 33(2), 162-168.
533. Hayatbakhsh, M.R., Alati, R., Hutchinson, D., Jamrozik, K., Najman, J.M., Mamun, A.A., O’Callaghan, M., & Bor, W. (2007). Association of maternal smoking and alcohol consumption with young adults’ cannabis use: A prospective study. American Journal of Epidemiology 166, 592-598.
534. Hayward, L., Mant, A., Eyland, E.A., Hewitt, H., Pond, C.D., & Saunders, N.A. (1992). Neuropsychological functioning and sleep patterns in the elderly. Medical Journal of Australia 157, 51-52.
535. Heather, N. (1988). Lessons from a controlled evaluation of a general practice minimal intervention for problem drinking. Australian Drug and Alcohol Review 7, 317-328.
536. Heather, N. (1989). Psychology and brief interventions. British Journal of Addiction 84, 357-370.
537. Heather, N. (1989). Disulfiram treatment for alcoholism: Deserves re-examination. British Medical Journal 299, 471-472.
538. Heather, N. (1989). Problem drinking as a form of learned behaviour. A reply to Gorman. British Journal of Addiction 84, 847-848.
539. Heather, N. (1989). Problem drinking as a form of learned behaviour: A final rejoinder to Gorman and Edwards. British Journal of Addiction 85, 617-620.
540. Heather, N. (1990). DRAMS. A reply from Nick Heather. Drug and Alcohol Review 9, 290.
541. Heather, N. (1992). Why alcoholism is not a disease. Medical Journal of Australia 156, 212-215.
542. Heather, N. (1992). Comments on S. Peele, ‘Alcoholism, politics and bureaucracy: The consensus against controlled- drinking therapy in America’. Addictive Behaviours 17, 73-74.
543. Heather, N. (1992). Addictive disorders are essentially motivational problems Commentary on Davidson’s ‘Prochaska and DiClemente’s model of change: A case study’. British Journal of Addiction 87, 825-835.
544. Heather, N. & Bradley, B.P. (1990). Cue exposure as a practical treatment for addictive disorders: Why are we waiting? Addictive Behaviours 15, 335-337.
545. Heather, N. & Greeley, J. (1990). Cue exposure in the treatment of drug dependence: The potential of a new method for preventing relapse. Drug and Alcohol Review 9, 155-168.
546. Heather, N., Kissoon-Singh, J., & Fenton, G.W. (1990). Assisted natural recovery from alcohol problems: Effects of a self-help manual with and without supplementary telephone contact. British Journal of Addiction 85, 1177-1185.
547. Heather, N., & Mattick, R.P. (1994). The development of guidelines for drug and alcohol dependence treatment: Affecting policy and practice. Drug and Alcohol Review 13, 119-126.
548. Heather, N. & Richmond, R. (1991). Research into brief interventions for excessive drinkers and smokers. Journal of Drug Issues 22, 641-660.
549. Heather, N., Stallard, A., & Tebbutt, J. (1991). Importance of substance cues in relapse among heroin users: Comparison of two methods of investigation. Addictive Behaviours 16, 41-49.
550. Heather, N. & Tebbutt, J. (1989). Definitions of non-abstinent and abstinent categories in alcoholism treatment outcome classifications. Drug and Alcohol Dependence 24, 83-93.
551. Heather, N., Tebbutt, J., Mattick, R.P., & Zamir, R. (1993). Development of a scale for measuring impaired control over alcohol consumption. Journal of Studies on Alcohol 58, 700-709.
552. Henderson, S., Andrews, G., & Hall, W. (2000) Australia’s mental health: An overview of the general population survey. Australian and New Zealand Journal of Psychiatry 34, 197-205. (abstract available)
553. Henderson, N. & Huon, G. (2002). Negative affect and binge eating in overweight women. British Journal of Health Psychology 7, 77-87.
554. Hickman, M., Taylor, C., Chatterjee, A., Degenhardt, L., Frischer, M., Hay, G., Tilling, K., Weissing, L., Griffiths, P., & McKetin, R. (2004). Estimating the prevalence of problematic drug use: A review of methods and their application. Bulletin on Narcotics, vol LIV, Nos 1 and 2, 15-32.
555. Hines, S., Theodorou, S., Williamson, A., Fong, D., & Curry, K. (2008). Management of acute pain in methadone mai